

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrDARZALEX[®]

daratumumab

20 mg/mL Concentrate for Solution for Infusion

Professed Standard

Antineoplastic, monoclonal antibody

Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.janssen.com/canada

Date of Initial Approval:
June 29, 2016

Date of Revision:
May 07, 2019

Submission Control No: 224102
All trademarks used under license
© 2019 Janssen Inc.

Table of Contents

| | |
|---|---------------|
| PART I: HEALTH PROFESSIONAL INFORMATION..... | 3 |
| SUMMARY PRODUCT INFORMATION | 3 |
| DESCRIPTION..... | 3 |
| INDICATIONS AND CLINICAL USE..... | 3 |
| CONTRAINDICATIONS | 4 |
| WARNINGS AND PRECAUTIONS..... | 4 |
| ADVERSE REACTIONS..... | 8 |
| DRUG INTERACTIONS | 28 |
| DOSAGE AND ADMINISTRATION | 29 |
| OVERDOSAGE | 34 |
| ACTION AND CLINICAL PHARMACOLOGY | 34 |
| STORAGE AND STABILITY..... | 38 |
| SPECIAL HANDLING INSTRUCTIONS | 39 |
| DOSAGE FORMS, COMPOSITION AND PACKAGING | 39 |
| PART II: SCIENTIFIC INFORMATION | 40 |
| PHARMACEUTICAL INFORMATION..... | 40 |
| CLINICAL TRIALS | 40 |
| TOXICOLOGY | 53 |
| REFERENCES | 55 |
| PART III: PATIENT MEDICATION INFORMATION | 56 |

PrDARZALEX[®]

daratumumab

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

| Route of Administration | Pharmaceutical Form/Strength | Clinically Relevant Nonmedicinal Ingredients |
|--------------------------------|---|--|
| Intravenous (IV) infusion | Concentrate for solution for infusion 20 mg/mL | None <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i> |

DESCRIPTION

DARZALEX[®] (daratumumab) is an IgG1κ human monoclonal antibody (mAb) that targets the CD38 protein expressed at a high level on the surface of cells in a variety of hematological malignancies, including multiple myeloma tumor cells. CD38 protein has multiple functions such as receptor mediated adhesion, signaling and enzymatic activity. Daratumumab inhibits the *in vivo* growth of CD38-expressing tumor cells. Based on *in vitro* studies, daratumumab may utilize multiple effector functions, resulting in immune mediated tumor cell death.

INDICATIONS AND CLINICAL USE

DARZALEX[®] (daratumumab) is indicated:

- in combination with bortezomib, melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
- in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD.

Marketing authorization was based on the primary efficacy endpoint of overall response rate demonstrated in a single-arm study. Progression-free survival and overall survival benefits cannot be characterized in a single-arm study (see **CLINICAL TRIALS**).

Geriatrics (≥65 years of age):

No overall differences in safety or effectiveness were observed between elderly and younger patients (see **ACTION AND CLINICAL PHARMACOLOGY**). No dose adjustments are considered necessary.

Pediatrics (<18 years of age):

The safety and efficacy of DARZALEX[®] have not been established in pediatric patients.

CONTRAINDICATIONS

DARZALEX[®] is contraindicated for patients with a history of severe hypersensitivity to daratumumab or who are hypersensitive to any ingredient in the formulation or component of the container. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the Product Monograph.

WARNINGS AND PRECAUTIONS**General**

DARZALEX[®] (daratumumab) should only be administered under the supervision of a healthcare professional experienced in the treatment of cancer.

DARZALEX[®] can be used in combination with other medications; therefore, the warnings and precautions applicable for use with those medications also apply to DARZALEX[®] combination therapy including the potential risk of fetal harm, the presence and transmission in sperm and blood, and prohibitions against blood and/or sperm donation. The prescribing information for all medications used in combination with DARZALEX[®] must be consulted before starting therapy. See *Special Populations: Pregnant Women and Nursing Women*.

Infusion-Related Reactions

DARZALEX[®] can cause serious infusion-related reactions (IRRs), including anaphylactic reactions.

In clinical trials, IRRs were reported in approximately half of all patients treated with DARZALEX[®]. The majority (96%) of infusion-related events occurred at the first infusion and most were Grade 1-2. IRRs can also occur with subsequent infusions. Four percent of patients had an IRR at more than one infusion.

Reactions occurred during or after completing DARZALEX[®] infusion (see **ADVERSE REACTIONS**). Most reactions occurred during infusion or within 4 hours of completing DARZALEX[®]. Prior to the introduction of post-infusion medication in clinical trials, IRRs occurred up to 48 hours after infusion.

Signs and symptoms may include respiratory symptoms, such as wheezing, larynx and throat tightness and irritation, laryngeal edema, pulmonary edema, and cytokine release syndrome. The

most common ($\geq 5\%$) symptoms were mostly mild to moderate in severity and included chills, cough, and dyspnea. Other symptoms were nasal congestion, throat irritation, bronchospasm, hypotension, headache, pyrexia, chest discomfort, wheezing, rash, urticaria, pruritus, allergic rhinitis, nausea, and vomiting. Severe IRRs (5.6%) including bronchospasm (1.1%), laryngeal edema (0.6%), pulmonary edema (0.1%), hypertension (1.5%), dyspnea (1.5%), and hypoxia (0.5%) were also reported (see **ADVERSE REACTIONS**). Patients should be monitored for symptoms of IRRs.

Pre-medicate patients with antihistamines, antipyretics and corticosteroids to reduce the risk of IRRs prior to treatment with DARZALEX[®]. Immediately interrupt DARZALEX[®] infusion for IRRs of any grade/severity and institute medical management or supportive treatment as needed. For patients with Grade 1, 2, or 3 reactions, interrupt DARZALEX[®] therapy and manage symptoms; reduce the infusion rate when re-starting the infusion. If an anaphylactic reaction or life threatening (Grade 4) IRR occurs, permanently discontinue administration of DARZALEX[®] and institute appropriate emergency care (see **DOSAGE AND ADMINISTRATION - Management of IRRs**).

To reduce the risk of delayed IRRs, administer oral corticosteroids to all patients after each infusion. Additionally, consider the use of post-infusion medications (e.g. inhaled corticosteroids, short and long acting bronchodilators) for patients with a history of chronic obstructive pulmonary disease to manage respiratory complications should they occur. Pre- and post-infusion medications may vary when DARZALEX[®] is used in combination therapy (see **DOSAGE AND ADMINISTRATION**).

Neutropenia/Thrombocytopenia

When used in combination with background therapy, DARZALEX[®] increases neutropenia and thrombocytopenia induced by the background therapy (see **ADVERSE REACTIONS**).

Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. DARZALEX[®] dose delay may be required to allow recovery of blood cell counts (neutrophils or platelets). No dose reduction of DARZALEX[®] is recommended. Consider supportive care with transfusions or growth factors as needed.

Infections

Patients treated with DARZALEX[®] in combination with lenalidomide or bortezomib/dexamethasone experienced a higher incidence of infections that could be severe, life-threatening and/or fatal, compared with those treated with lenalidomide or bortezomib/dexamethasone alone (see **ADVERSE REACTIONS**). Patients should be monitored for signs and symptoms of infection, and treated promptly.

Hepatitis B Virus Reactivation

Hepatitis B Virus (HBV) reactivation, in some cases fatal, has been reported in patients treated with DARZALEX[®]. HBV screening should be performed in all patients before initiation of treatment with DARZALEX[®].

For patients with evidence of positive HBV serology, monitor for clinical and laboratory signs of HBV reactivation during, and for at least six months following the end of DARZALEX[®] treatment. Manage patients according to current clinical guidelines. Consider consulting a hepatitis disease expert as clinically indicated.

In patients who develop reactivation of HBV while on DARZALEX[®], suspend treatment with DARZALEX[®] and any concomitant steroids, chemotherapy, and institute appropriate treatment. Resumption of DARZALEX[®] treatment in patients whose HBV reactivation is adequately controlled should be discussed with physicians with expertise in managing HBV.

Interference with indirect antiglobulin test (indirect Coombs test)

Daratumumab binds to CD38 found at low levels on red blood cells (RBCs) and may result in a positive indirect Coombs test. Daratumumab-mediated positive indirect Coombs test may persist for up to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum (see **DRUG INTERACTIONS**). The determination of a patient's ABO and Rhesus (Rh) blood type are not impacted.

Patient's blood should be typed and screened prior to starting DARZALEX[®]. In the event of a planned transfusion notify blood transfusion centers of this interference with serological testing.

Interference with determination of complete response

Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein. In patients with persistent very good partial response, consider other methods to evaluate the depth of response (see **DRUG INTERACTIONS**).

Special Populations:

Pregnant Women:

Risks of DARZALEX[®] use in pregnant women have not been assessed. Animal studies have not been conducted. However, immunoglobulin G1 (IgG1) monoclonal antibodies are known to transfer across the placenta. Mice that were genetically modified to eliminate all CD38 expression (CD38 knockout mice) had reduced bone density at birth that recovered by 5 months of age. In cynomolgus monkeys exposed during pregnancy to other monoclonal antibodies that affect leukocyte populations, infant monkeys had a reversible reduction in leukocytes.

Based on its mechanism of action, DARZALEX[®] may cause fetal myeloid or lymphoid-cell depletion and decreased bone density (see **TOXICOLOGY**).

DARZALEX[®] should not be used during pregnancy unless the benefit of treatment to the woman is considered to outweigh the potential risks to the fetus. If the patient becomes pregnant while taking this drug, the patient should be informed of the potential risk to the fetus. Defer administering live vaccines to neonates and infants exposed to DARZALEX[®] in utero until a hematology evaluation is completed.

Women of childbearing potential should use effective contraception during treatment and for at least 3 months after cessation of DARZALEX[®] treatment.

In combination treatment, DARZALEX[®] is administered with lenalidomide/dexamethasone, bortezomib/dexamethasone, or bortezomib/melphalan/prednisone. Lenalidomide can cause embryo-fetal harm and is contraindicated for use in pregnancy due to the potential for lenalidomide to cause fetal harm, including severe life-threatening human birth defects. Bortezomib has caused post-implantation loss in animals. Placental transfer studies have not been conducted with bortezomib and adequate and well-controlled studies have not been conducted in pregnant women. Safe use of melphalan has not been established with respect to adverse effects on fetal development. Refer to the Product Monograph for lenalidomide, bortezomib, or melphalan for requirements regarding contraception and for additional details.

Nursing Women: It is not known whether daratumumab is excreted into human or animal milk or affects milk production. There are no studies to assess the effect of daratumumab on the breast-fed infant.

Human IgG is excreted in breast milk. Because the risks of DARZALEX[®] to the nursing infant are unknown, a decision should be made whether to discontinue breast-feeding, or discontinue DARZALEX[®] therapy, taking into account the benefit of breast feeding for the child and the benefit of DARZALEX[®] therapy for the woman.

As there is potential for serious adverse reactions in breast-fed infants from DARZALEX[®] administered in combination with lenalidomide and dexamethasone, breast-feeding is not recommended. For DARZALEX[®] administered in combination with bortezomib and dexamethasone, it is not known whether bortezomib is excreted in milk. Refer to the lenalidomide, bortezomib, and dexamethasone Product Monographs for additional information.

Pediatrics (< 18 years of age): The safety and efficacy of DARZALEX[®] have not been established in pediatric patients.

Geriatrics (> 65 years of age): No overall differences in safety or effectiveness were observed between elderly and younger patients (see **ACTION AND CLINICAL PHARMACOLOGY**). No dose adjustments are considered necessary.

Hepatic Impairment:

No formal studies of DARZALEX[®] in patients with hepatic impairment have been conducted. No dosage adjustments are necessary for patients with mild hepatic impairment (Total Bilirubin [TB] 1.0 to 1.5 times upper limit of normal [ULN] or aspartate aminotransferase [AST] >ULN). Daratumumab has been studied in a limited number of patients with moderate (TB >1.5 to 3.0 times ULN) to severe (TB >3.0 times ULN) and therefore no dose recommendations can be made in these patient populations (see **ACTION AND CLINICAL PHARMACOLOGY**).

Renal Impairment:

No formal studies of DARZALEX[®] in patients with renal impairment have been conducted. No dosage adjustment is necessary for patients with renal impairment (see **ACTION AND CLINICAL PHARMACOLOGY**).

ADVERSE REACTIONS**Adverse Drug Reaction Overview****Patients with newly diagnosed multiple myeloma who are ineligible for ASCT**

The safety of DARZALEX[®] in combination with bortezomib, melphalan, and prednisone (D-VMP) was evaluated in a phase III, randomized, open-label study in patients with newly diagnosed multiple myeloma (MMY3007; n=700). The most frequently reported TEAEs (≥20%) in the D-VMP arm were: infusion-related reactions, neutropenia, thrombocytopenia, anemia, upper respiratory tract infection, pyrexia, diarrhea, nausea, and peripheral sensory neuropathy. The overall incidence of serious TEAEs was 41.6% in the D-VMP arm and 32.5% in the VMP arm. Serious TEAEs (≥2%) with at least a 2% higher incidence in the D-VMP arm compared to the VMP arm included infections (23.1% vs 11.9%), including pneumonia (D-VMP 10.1% vs VMP 3.1%). Study treatment discontinuation due to a TEAE occurred in 4.9% of subjects in the D-VMP group, and 9.0% in the VMP group.

Patients with multiple myeloma who have received at least one prior therapy

The data described below reflect exposure to DARZALEX[®] in two Phase 3 active-controlled trials that included 423 patients with multiple myeloma treated with DARZALEX[®] at 16 mg/kg in combination with either lenalidomide and dexamethasone (DRd) [Study MMY3003] or bortezomib and dexamethasone (DVd) [Study MMY3004].

Patients with multiple myeloma who received DARZALEX[®] in combination with lenalidomide/dexamethasone

The safety of DARZALEX[®] in combination with lenalidomide and dexamethasone was evaluated in a phase III, randomized, open-label study in patients with relapsed/refractory multiple myeloma after at least one prior therapy (n=569). In MMY3003, the most frequently reported TEAEs (≥20%) in the DRd arm were: infusion-related reactions, neutropenia, thrombocytopenia, anemia, diarrhea, constipation, upper respiratory tract infection, pneumonia, cough, dyspnea, nausea, fatigue, muscle spasms, insomnia, and pyrexia. The overall incidence of serious TEAEs was 54.1% in the DRd arm and 44.8% in the Rd arm. Serious TEAEs (≥2%) with at least a 2% higher incidence in the DRd arm compared to the Rd arm included infections (33.6% vs 23.8%) such as influenza (DRd 3.9% vs Rd 1.4%) and febrile neutropenia (DRd 4.2% vs Rd 1.4%). Study treatment discontinuation due to a TEAE occurred in 16.3% of subjects in the DRd group, and 13.9% in the Rd group. The most common TEAEs leading to study treatment discontinuation were pneumonia, septic shock and fatigue (each 1.4%), and general physical health deterioration (1.1%) in the DRd group, and pulmonary embolism (1.1%) in the Rd group.

Patients with multiple myeloma who received DARZALEX[®] in combination with bortezomib/dexamethasone

The safety of DARZALEX[®] in combination with bortezomib and dexamethasone was evaluated in a phase III, randomized, open-label clinical study in multiple myeloma patients (n=498) who had received at least one prior therapy. In study MMY3004, the most frequently reported TEAEs ($\geq 20\%$) for the DVd group were: infusion-related reactions, thrombocytopenia, anemia, peripheral sensory neuropathy, diarrhea, constipation, upper respiratory tract infection, cough, and fatigue. The overall incidence of serious TEAEs was 49% of patients in the DVd group and 34% in the Vd group. Serious TEAEs with at least a 2% higher incidence in the DVd arm compared to the Vd arm included anemia (DVd 3.3% vs Vd 0.4%), bronchitis (DVd 2.9% vs Vd 0.8%), thrombocytopenia (DVd 2.5% vs Vd 0.4%), atrial fibrillation (DVd 2.5% vs Vd 0%) and second primary malignancy (3.7% vs 0.4%). TEAEs resulting in treatment discontinuation occurred in 9.3% (n=22) of subjects in the DVd group, and 9.1% (n=22) in the Vd group.

Patients with multiple myeloma who have received at least three prior lines of therapy including a PI and an IMiD, or who are refractory to both a PI and an IMiD

The data described below reflect exposure to DARZALEX[®] in three pooled open label clinical studies that included 156 patients with relapsed and refractory multiple myeloma treated with DARZALEX[®] at 16 mg/kg. The median duration of DARZALEX[®] treatment was 3.3 months (range: 0.03 to 41.5 months).

Infusion-related reactions were the most frequently observed treatment-emergent adverse events [TEAEs] and occurred in 48% of patients treated at 16 mg/kg.

Other frequently reported ($\geq 20\%$) adverse events included fatigue, pyrexia, upper respiratory tract infection, nausea, back pain, cough, anemia, neutropenia and thrombocytopenia.

Grade 3 or 4 TEAEs were reported for 57.1% of patients. The most commonly reported Grade 3 or 4 TEAEs ($\geq 10\%$) were anemia (17%, all Grade 3), thrombocytopenia (8.3% Grade 3, 5.8% Grade 4), and neutropenia (9.6% Grade 3, 2.6% Grade 4).

The most common ($\geq 2\%$) serious TEAEs were pneumonia (6%), general physical health deterioration, hypercalcemia and pyrexia (each at 3%), cross-match incompatible and herpes zoster (each at 2%). Four percent of patients discontinued DARZALEX[®] treatment due to an adverse event. The adverse events leading to discontinuation were general physical health deterioration, H1N1 influenza, hypercalcemia, pneumonia, and spinal cord compression. The median time to discontinuation was 21.5 days (1.0, 106.0). Adverse events leading to treatment delay were observed in 25 (16.0%) of patients, and the most frequent adverse event was infections, reported in 14 (9.0%) patients.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Patients with newly diagnosed multiple myeloma who are ineligible for ASCT

Study MMY3007

TEAEs described in Table 1 reflect exposure to DARZALEX[®] (daratumumab) in combination with bortezomib, melphalan, and prednisone (D-VMP) for a median treatment duration of 14.7 months (range: 0 to 25.8 months) and median treatment duration of 12 months (range: 0.1 to 14.8 months) for the bortezomib, melphalan, and prednisone (VMP) group.

Infusion-related reactions (including terms determined by investigators to be related to infusion; see **Infusion-related Reactions**) were reported in 27.7% of patients in the D-VMP group.

Table 1: Number of Subjects With 1 or More Treatment-emergent Adverse Events (≥ 5%) in Patients Treated with D-VMP by MedDRA System-Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54767414MMY3007)

| | VMP | | D-VMP | |
|--|---------------------|-----------------------|---------------------|-----------------------|
| | All Grades n (%) | Grade 3 or 4 n (%) | All Grades n (%) | Grade 3 or 4 n (%) |
| Analysis set: safety | 354 | | 346 | |
| MedDRA system organ class / preferred term | | | | |
| Blood and lymphatic system disorders | | | | |
| Neutropenia | 186 (52.5%) | 137 (38.7%) | 172 (49.7%) | 138 (39.9%) |
| Thrombocytopenia | 190 (53.7%) | 133 (37.6%) | 169 (48.8%) | 119 (34.4%) |
| Anaemia | 133 (37.6%) | 70 (19.8%) | 97 (28.0%) | 55 (15.9%) |
| Leukopenia | 53 (15.0%) | 30 (8.5%) | 46 (13.3%) | 28 (8.1%) |
| Lymphopenia | 36 (10.2%) | 22 (6.2%) | 37 (10.7%) | 26 (7.5%) |
| Infections and infestations | | | | |
| Upper respiratory tract infection | 49 (13.8%) | 5 (1.4%) | 91 (26.3%) | 7 (2.0%) |
| Pneumonia | 17 (4.8%) | 14 (4.0%) | 53 (15.3%) | 39 (11.3%) |
| Bronchitis | 27 (7.6%) | 3 (0.8%) | 50 (14.5%) | 8 (2.3%) |
| Urinary tract infection | 12 (3.4%) | 1 (0.3%) | 29 (8.4%) | 6 (1.7%) |
| Nasopharyngitis | 20 (5.6%) | 0 | 19 (5.5%) | 0 |
| General disorders and administration site conditions | | | | |
| Pyrexia | 74 (20.9%) | 2 (0.6%) | 80 (23.1%) | 2 (0.6%) |
| Oedema peripheral | 39 (11.0%) | 1 (0.3%) | 62 (17.9%) | 3 (0.9%) |
| Fatigue | 51 (14.4%) | 9 (2.5%) | 48 (13.9%) | 11 (3.2%) |
| Asthenia | 42 (11.9%) | 7 (2.0%) | 40 (11.6%) | 4 (1.2%) |
| Chills | 6 (1.7%) | 0 | 26 (7.5%) | 0 |
| Gastrointestinal disorders | | | | |
| Diarrhoea | 87 (24.6%) | 11 (3.1%) | 82 (23.7%) | 9 (2.6%) |
| Nausea | 76 (21.5%) | 4 (1.1%) | 72 (20.8%) | 3 (0.9%) |
| Constipation | 65 (18.4%) | 1 (0.3%) | 63 (18.2%) | 3 (0.9%) |
| Vomiting | 55 (15.5%) | 6 (1.7%) | 59 (17.1%) | 5 (1.4%) |
| Abdominal pain | 25 (7.1%) | 0 | 18 (5.2%) | 1 (0.3%) |
| Dyspepsia | 12 (3.4%) | 0 | 18 (5.2%) | 0 |
| Nervous system disorders | | | | |
| Peripheral sensory neuropathy | 121 (34.2%) | 14 (4.0%) | 98 (28.3%) | 5 (1.4%) |
| Neuralgia | 16 (4.5%) | 0 | 25 (7.2%) | 1 (0.3%) |
| Headache | 14 (4.0%) | 1 (0.3%) | 23 (6.6%) | 0 |
| Dizziness | 22 (6.2%) | 1 (0.3%) | 22 (6.4%) | 1 (0.3%) |
| Musculoskeletal and connective tissue disorders | | | | |
| Back pain | 42 (11.9%) | 4 (1.1%) | 48 (13.9%) | 6 (1.7%) |
| Pain in extremity | 22 (6.2%) | 1 (0.3%) | 29 (8.4%) | 0 |
| Arthralgia | 22 (6.2%) | 0 | 27 (7.8%) | 0 |
| Bone pain | 9 (2.5%) | 0 | 20 (5.8%) | 4 (1.2%) |
| Respiratory, thoracic and mediastinal disorders | | | | |
| Cough | 27 (7.6%) | 1 (0.3%) | 52 (15.0%) | 1 (0.3%) |
| Dyspnoea | 16 (4.5%) | 3 (0.8%) | 43 (12.4%) | 9 (2.6%) |
| Metabolism and nutrition disorders | | | | |
| Decreased appetite | 46 (13.0%) | 1 (0.3%) | 40 (11.6%) | 2 (0.6%) |
| Hyperglycaemia | 13 (3.7%) | 8 (2.3%) | 21 (6.1%) | 10 (2.9%) |
| Hypocalcaemia | 17 (4.8%) | 8 (2.3%) | 20 (5.8%) | 8 (2.3%) |
| Hypokalaemia | 17 (4.8%) | 6 (1.7%) | 19 (5.5%) | 5 (1.4%) |
| Skin and subcutaneous tissue disorders | | | | |
| Rash | 39 (11.0%) | 2 (0.6%) | 29 (8.4%) | 1 (0.3%) |
| Pruritus | 10 (2.8%) | 1 (0.3%) | 19 (5.5%) | 0 |
| Vascular disorders | | | | |
| Hypertension | 11 (3.1%) | 6 (1.7%) | 35 (10.1%) | 14 (4.0%) |
| Hypotension | 24 (6.8%) | 2 (0.6%) | 31 (9.0%) | 2 (0.6%) |
| Psychiatric disorders | | | | |
| Insomnia | 32 (9.0%) | 2 (0.6%) | 26 (7.5%) | 1 (0.3%) |

Table 1: Number of Subjects With 1 or More Treatment-emergent Adverse Events (≥ 5%) in Patients Treated with D-VMP by MedDRA System-Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54767414MMY3007)

| | VMP | | D-VMP | |
|--|---------------------|-----------------------|---------------------|-----------------------|
| | All Grades n (%) | Grade 3 or 4 n (%) | All Grades n (%) | Grade 3 or 4 n (%) |

Key: VMP=bortezomib-melphalan-prednisone; D-VMP=daratumumab-bortezomib-melphalan-prednisone.

Key: TEAE = treatment-emergent adverse event.

Note: Adverse events are reported using MedDRA version 20.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

Less Common Clinical Trial Adverse Events (Study MMY3007)

Other TEAEs (<5% and ≥2% in the D-VMP arm) of clinical relevance include:

Infections and infestations: herpes zoster, lower respiratory tract infection, viral upper respiratory tract infection, pharyngitis, sinusitis, influenza, oral herpes, respiratory tract infection.

Gastrointestinal disorders: abdominal distension, abdominal pain or discomfort, stomatitis.

General disorders and administration site conditions: influenza-like illness, injection site erythema, malaise, non-cardiac chest pain, peripheral swelling.

Respiratory, thoracic and mediastinal disorders: oropharyngeal pain, bronchospasm, catarrh, epistaxis, nasal congestion, pleural effusion, pulmonary edema.

Musculoskeletal and connective tissue disorders: myalgia, musculoskeletal pain, musculoskeletal chest pain.

Nervous system disorders: paraesthesia, dysgeusia, peripheral sensorimotor neuropathy, syncope, tremor.

Metabolism and nutritional disorders: hyperuricemia, hyperkalemia, hyponatremia, dehydration, hypoalbuminemia.

Psychiatric disorders: depression, confusional state.

Investigations: alanine aminotransferase increased, aspartate aminotransferase increased, weight decreased, gamma-glutamyltransferase increased, blood alkaline phosphatase increased, blood creatinine increased, oxygen saturation decreased.

Renal and urinary disorders: dysuria, acute kidney injury.

Injury, poisoning and procedural complications: fall, spinal compression fracture, contusion.

Cardiac disorders: atrial fibrillation.

Abnormal Hematologic and Clinical Chemistry Findings (Study MMY3007)

Laboratory abnormalities worsening during treatment from baseline are listed in Table 2.

Table 2: Treatment-emergent hematology laboratory abnormalities in Study MMY3007

| | Study MMY3007 | | | | | |
|------------------|--------------------|------------------|------------------|--------------------|------------------|------------------|
| | D-VMP (n=346) | | | VMP (n=354) | | |
| | Any Grade n (%) | Grade 3 n (%) | Grade 4 n (%) | Any Grade n (%) | Grade 3 n (%) | Grade 4 n (%) |
| Anemia | 161 (47) | 61 (18) | 0 | 177 (50) | 75 (21) | 0 |
| Thrombocytopenia | 305 (88) | 92 (27) | 39 (11) | 311 (88) | 91 (26) | 56 (16) |
| Neutropenia | 297 (86) | 116 (34) | 34 (10) | 307 (87) | 112 (32) | 38 (11) |
| Lymphopenia | 293 (85) | 158 (46) | 43 (12) | 294 (83) | 155 (44) | 33 (9) |

Key: D=Daratumumab, VMP=bortezomib-melphalan-prednisone.

The incidence of Grade 3 or 4 febrile neutropenia was 1.2% (D-VMP) and 2.2% (VMP).

Patients with multiple myeloma who have received at least one prior therapy

Study MMY3003

TEAEs described in Table 3 reflect exposure to DARZALEX[®] (daratumumab) in combination with lenalidomide and dexamethasone (DRd) for a median treatment duration of 16.6 months (range: 0 to 24.4 months) and to lenalidomide and dexamethasone (Rd) for a median treatment duration of 14.8 months (range: 0.2 to 24.0 months).

Infusion-related reactions (including terms determined by investigators to be related to infusion; see **Infusion-related Reactions**) were reported in 48% of patients in the DRd group.

Table 3: Number of Subjects With 1 or More Treatment-emergent Adverse Events ($\geq 5\%$) in patients treated with DRd by MedDRA System-Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54767414MMY3003)

| | MMY3003 | | | |
|--|---------------|---------------|---------------|---------------|
| | Rd (N=281) | | DRd (N=283) | |
| | Any Grade (%) | Grade 3/4 (%) | Any Grade (%) | Grade 3/4 (%) |
| Infections and infestations | | | | |
| Upper respiratory tract infection ^a | 147 (52.3%) | 12 (4.3%) | 194 (68.6%) | 21 (7.4%) |
| Pneumonia ^b | 43 (15.3%) | 26 (9.3%) | 62 (21.9%) | 40 (14.1%) |
| Influenza | 14 (5.0%) | 2 (0.7%) | 25 (8.8%) | 9 (3.2%) |
| Lower respiratory tract infection ^c | 9 (3.2%) | 3 (1.1%) | 19 (6.7%) | 5 (1.8%) |
| Urinary tract infection | 12 (4.3%) | 1 (0.4%) | 17 (6.0%) | 5 (1.8%) |
| Gastrointestinal disorders | | | | |
| Diarrhoea | 79 (28.1%) | 9 (3.2%) | 133 (47.0%) | 18 (6.4%) |
| Constipation | 72 (25.6%) | 2 (0.7%) | 84 (29.7%) | 3 (1.1%) |
| Nausea | 44 (15.7%) | 1 (0.4%) | 71 (25.1%) | 4 (1.4%) |
| Vomiting | 17 (6.0%) | 3 (1.1%) | 48 (17.0%) | 3 (1.1%) |
| Abdominal pain upper | 10 (3.6%) | 0 | 22 (7.8%) | 0 |
| Abdominal pain | 11 (3.9%) | 0 | 20 (7.1%) | 0 |
| Dyspepsia | 7 (2.5%) | 0 | 19 (6.7%) | 0 |
| Stomatitis | 6 (2.1%) | 0 | 18 (6.4%) | 0 |
| General disorders and administration site conditions | | | | |
| Fatigue | 82 (29.2%) | 9 (3.2%) | 100 (35.3%) | 18 (6.4%) |
| Pyrexia | 32 (11.4%) | 4 (1.4%) | 60 (21.2%) | 6 (2.1%) |
| Oedema peripheral ^d | 44 (15.7%) | 3 (1.1%) | 54 (19.1%) | 2 (0.7%) |
| Asthenia | 37 (13.2%) | 8 (2.8%) | 48 (17.0%) | 9 (3.2%) |
| Chills | 9 (3.2%) | 0 | 18 (6.4%) | 1 (0.4%) |
| Influenza like illness | 13 (4.6%) | 1 (0.4%) | 17 (6.0%) | 0 |
| Blood and lymphatic system disorders | | | | |
| Neutropenia ^e | 124 (44.1%) | 109 (38.8%) | 169 (59.7%) | 149 (52.7%) |
| Anaemia | 102 (36.3%) | 58 (20.6%) | 97 (34.3%) | 39 (13.8%) |
| Thrombocytopenia | 85 (30.2%) | 43 (15.3%) | 79 (27.9%) | 38 (13.4%) |
| Leukopenia | 18 (6.4%) | 7 (2.5%) | 21 (7.4%) | 8 (2.8%) |
| Lymphopenia | 15 (5.3%) | 10 (3.6%) | 17 (6.0%) | 15 (5.3%) |
| Respiratory, thoracic and mediastinal disorders | | | | |
| Cough ^f | 42 (14.9%) | 0 | 90 (31.8%) | 0 |
| Dyspnoea ^g | 38 (13.5%) | 2 (0.7%) | 64 (22.6%) | 10 (3.5%) |
| Nasal congestion | 5 (1.8%) | 0 | 15 (5.3%) | 0 |
| Rhinitis allergic | 3 (1.1%) | 0 | 15 (5.3%) | 0 |
| Musculoskeletal and connective tissue disorders | | | | |
| Muscle spasms | 57 (20.3%) | 5 (1.8%) | 77 (27.2%) | 2 (0.7%) |
| Back pain | 49 (17.4%) | 4 (1.4%) | 52 (18.4%) | 4 (1.4%) |
| Arthralgia | 25 (8.9%) | 1 (0.4%) | 29 (10.2%) | 3 (1.1%) |
| Muscular weakness | 26 (9.3%) | 2 (0.7%) | 24 (8.5%) | 0 |
| Pain in extremity | 34 (12.1%) | 1 (0.4%) | 24 (8.5%) | 0 |
| Bone pain | 14 (5.0%) | 1 (0.4%) | 21 (7.4%) | 2 (0.7%) |
| Musculoskeletal pain | 18 (6.4%) | 3 (1.1%) | 20 (7.1%) | 1 (0.4%) |
| Musculoskeletal chest pain | 17 (6.0%) | 0 | 16 (5.7%) | 1 (0.4%) |
| Myalgia | 10 (3.6%) | 0 | 16 (5.7%) | 0 |
| Nervous system disorders | | | | |
| Headache | 21 (7.5%) | 0 | 41 (14.5%) | 0 |
| Tremor | 24 (8.5%) | 0 | 26 (9.2%) | 1 (0.4%) |
| Peripheral sensory neuropathy | 21 (7.5%) | 1 (0.4%) | 25 (8.8%) | 1 (0.4%) |
| Dizziness | 24 (8.5%) | 0 | 23 (8.1%) | 0 |
| Dysgeusia | 16 (5.7%) | 0 | 23 (8.1%) | 0 |
| Neuropathy peripheral | 15 (5.3%) | 1 (0.4%) | 16 (5.7%) | 2 (0.7%) |
| Metabolism and nutrition disorders | | | | |

Table 3: Number of Subjects With 1 or More Treatment-emergent Adverse Events (≥5%) in patients treated with DRd by MedDRA System-Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54767414MMY3003)

| | MMY3003 | | | |
|--|---------------|---------------|---------------|---------------|
| | Rd (N=281) | | DRd (N=283) | |
| | Any Grade (%) | Grade 3/4 (%) | Any Grade (%) | Grade 3/4 (%) |
| Decreased appetite | 32 (11.4%) | 1 (0.4%) | 36 (12.7%) | 4 (1.4%) |
| Hypokalaemia | 23 (8.2%) | 7 (2.5%) | 34 (12.0%) | 10 (3.5%) |
| Hyperglycaemia | 22 (7.8%) | 10 (3.6%) | 27 (9.5%) | 11 (3.9%) |
| Hypocalcaemia | 11 (3.9%) | 2 (0.7%) | 19 (6.7%) | 4 (1.4%) |
| Hypophosphataemia | 11 (3.9%) | 7 (2.5%) | 17 (6.0%) | 12 (4.2%) |
| Skin and subcutaneous tissue disorders | | | | |
| Rash ^h | 33 (11.7%) | 0 | 49 (17.3%) | 2 (0.7%) |
| Pruritus | 29 (10.3%) | 0 | 29 (10.2%) | 2 (0.7%) |
| Hyperhidrosis | 8 (2.8%) | 0 | 22 (7.8%) | 0 |
| Psychiatric disorders | | | | |
| Insomnia | 59 (21.0%) | 3 (1.1%) | 61 (21.6%) | 2 (0.7%) |
| Anxiety | 13 (4.6%) | 2 (0.7%) | 21 (7.4%) | 1 (0.4%) |
| Depression | 8 (2.8%) | 0 | 20 (7.1%) | 2 (0.7%) |
| Vascular disorders | | | | |
| Hypertension ⁱ | 10 (3.6%) | 2 (0.7%) | 27 (9.5%) | 11 (3.9%) |
| Hypotension | 6 (2.1%) | 1 (0.4%) | 20 (7.1%) | 2 (0.7%) |
| Eye disorders | | | | |
| Cataract | 14 (5.0%) | 6 (2.1%) | 26 (9.2%) | 7 (2.5%) |
| Vision blurred | 16 (5.7%) | 0 | 23 (8.1%) | 0 |
| Investigations | | | | |
| Weight decreased | 11 (3.9%) | 1 (0.4%) | 19 (6.7%) | 0 |
| Alanine aminotransferase increased | 11 (3.9%) | 3 (1.1%) | 16 (5.7%) | 7 (2.5%) |
| Renal and urinary disorders | | | | |
| Renal impairment | 13 (4.6%) | 1 (0.4%) | 22 (7.8%) | 1 (0.4%) |

Key: DRd=Daratumumab-lenalidomide-dexamethasone, Rd=lenalidomide-dexamethasone.

^a “Upper respiratory tract infection” includes bronchitis, sinusitis, respiratory tract infection viral, rhinitis, pharyngitis, respiratory tract infection, metapneumovirus infection, tracheobronchitis, viral upper respiratory tract infection, laryngitis, respiratory syncytial virus infection, staphylococcal pharyngitis, tonsillitis, viral pharyngitis, acute sinusitis, nasopharyngitis, bronchiolitis, bronchitis viral, pharyngitis streptococcal, tracheitis, upper respiratory tract infection bacterial, bronchitis bacterial, epiglottitis, laryngitis viral, oropharyngeal candidiasis, respiratory moniliasis, viral rhinitis, acute tonsillitis, rhinovirus infection.

^b “Pneumonia” includes lobar pneumonia, pneumonia cytomegaloviral, pneumocystis jirovecii pneumonia, pneumonia pneumococcal, bronchopneumonia, lung infection, pulmonary sepsis, pneumonia legionelle, pneumonia bacterial, pneumonia influenza, pneumonia haemophilus, pneumonia Klebsiella, pneumonia streptococcal, pneumonia aspiration, pneumonia viral

^c “Lower respiratory tract infection” includes lower respiratory tract infection and lower respiratory tract infection viral

^d “Oedema peripheral” includes oedema, generalised oedema, peripheral swelling

^e “Neutropenia” includes febrile neutropenia

^f “Cough” includes productive cough, allergic cough

^g “Dyspnoea” include dyspnoea exertional

^h “Rash” includes rash erythematous, rash maculo-papular, rash pruritic, rash macular

ⁱ “Hypertension” includes blood pressure increased

Note: Adverse events are reported using MedDRA version 18.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

Less Common Clinical Trial Adverse Events (Study MMY3003)

Other TEAEs (<5% in the DRd arm) of clinical relevance include:

Infections and infestations: conjunctivitis, gastroenteritis, herpes zoster, oral candidiasis, oral herpes.

Gastrointestinal disorders: toothache, abdominal distension, dry mouth, mouth ulceration, abdominal discomfort, dysphagia, hemorrhoids.

General disorders and administration site conditions: non-cardiac chest pain, malaise, chest discomfort.

Respiratory, thoracic and mediastinal disorders: dysphonia, nasal congestion, bronchospasm, rhinitis allergic, oropharyngeal pain, rhinorrhea, throat irritation, epistaxis, wheezing, hiccups, pulmonary embolism, hypoxia, laryngeal edema.

Musculoskeletal and connective tissue disorders: neck pain, pain in jaw, spinal pain.

Nervous system disorders: paraesthesia, hypoesthesia neuropathy peripheral, syncope, lethargy.

Metabolism and nutritional disorders: dehydration, hypomagnesemia, hyponatremia, hyperuricemia.

Skin and subcutaneous tissue disorders: dry skin, urticaria, erythema.

Psychiatric disorders: restlessness, agitation, irritability, mood altered.

Vascular disorders: flushing.

Investigations: aspartate aminotransferase increased, blood creatinine increased, gamma-glutamyltransferase increased, blood alkaline phosphatase increased.

Eye disorders: eye irritation, lacrimation increased.

Renal and urinary disorders: pollakiuria.

Injury, poisoning and procedural complications: fall, contusion.

Cardiac disorders: atrial fibrillation, tachycardia, angina pectoris.

Ear and labyrinth disorders: tinnitus.

Abnormal Hematologic and Clinical Chemistry Findings (Study MMY3003)

Laboratory abnormalities worsening during treatment from baseline are listed in Table 4.

Table 4: Treatment-emergent hematology laboratory abnormalities in Study MMY3003

| | Study MMY3003 | | | | | |
|------------------|--------------------|------------------|------------------|--------------------|------------------|------------------|
| | DRd (N=283) | | | Rd (N=281) | | |
| | Any Grade n (%) | Grade 3 n (%) | Grade 4 n (%) | Any Grade n (%) | Grade 3 n (%) | Grade 4 n (%) |
| Anemia | 150 (53) | 42 (15) | 0 | 167 (59) | 55 (20) | 0 |
| Thrombocytopenia | 209 (74) | 20 (7) | 20 (7) | 191 (68) | 31 (11) | 18 (6) |
| Neutropenia | 261 (92) | 103 (36) | 50 (18) | 246 (88) | 94 (33) | 24 (9) |
| Lymphopenia | 269 (95) | 118 (42) | 30 (11) | 246 (88) | 93 (33) | 20 (7) |

Key: D=Daratumumab, Rd=lenalidomide-dexamethasone.

The incidence of Grade 3 or 4 febrile neutropenia was 6% (DRd) and 3% (Rd). The incidence of all grade bleeding events was 20% (DRd) and 15% (Rd), and serious bleeding events were 1.4%

(DRd) and 1.8% (Rd).

Study MMY3004

TEAEs described in Table 5 reflect exposure to DARZALEX[®] in combination with bortezomib and dexamethasone (DVd) for a median treatment duration of 11.1 months (range: 0 to 21.2 months) and to bortezomib and dexamethasone (Vd) for a median treatment duration of 5.2 months (range: 0.2 to 8.0 months).

Infusion-related reactions (including terms determined by investigators to be related to infusion; see **Infusion-related Reactions**) were reported in 45% of patients in the DVd group.

Table 5: Number of Subjects With 1 or More Treatment-emergent Adverse Events ($\geq 5\%$) in patients treated with DVd by MedDRA System-Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54767414MMY3004)

| | MMY3004 | | | |
|--|---------------|---------------|---------------|---------------|
| | Vd (N=237) | | DVd (N=243) | |
| | Any Grade (%) | Grade 3/4 (%) | Any Grade (%) | Grade 3/4 (%) |
| Infections and infestations | | | | |
| Upper respiratory tract infection ^a | 73 (30.8%) | 6 (2.5%) | 119 (49.0%) | 19 (7.8%) |
| Pneumonia ^b | 33 (13.9%) | 25 (10.5%) | 44 (18.1%) | 32 (13.2%) |
| Conjunctivitis | 8 (3.4%) | 1 (0.4%) | 22 (9.1%) | 0 |
| Herpes zoster | 7 (3.0%) | 1 (0.4%) | 15 (6.2%) | 6 (2.5%) |
| Urinary tract infection | 6 (2.5%) | 1 (0.4%) | 15 (6.2%) | 2 (0.8%) |
| Blood and lymphatic system disorders | | | | |
| Thrombocytopenia | 105 (44.3%) | 78 (32.9%) | 145 (59.7%) | 110 (45.3%) |
| Anaemia | 75 (31.6%) | 38 (16.0%) | 67 (27.6%) | 36 (14.8%) |
| Neutropenia ^c | 23 (9.7%) | 11 (4.6%) | 46 (18.9%) | 33 (13.6%) |
| Lymphopenia | 9 (3.8%) | 6 (2.5%) | 32 (13.2%) | 24 (9.9%) |
| Leukopenia | 12 (5.1%) | 5 (2.1%) | 21 (8.6%) | 6 (2.5%) |
| Nervous system disorders | | | | |
| Peripheral sensory neuropathy | 90 (38.0%) | 16 (6.8%) | 120 (49.4%) | 11 (4.5%) |
| Neuralgia | 26 (11.0%) | 2 (0.8%) | 33 (13.6%) | 2 (0.8%) |
| Headache | 14 (5.9%) | 0 | 27 (11.1%) | 1 (0.4%) |
| Dizziness | 25 (10.5%) | 0 | 25 (10.3%) | 1 (0.4%) |
| Gastrointestinal disorders | | | | |
| Diarrhoea | 53 (22.4%) | 3 (1.3%) | 83 (34.2%) | 9 (3.7%) |
| Constipation | 38 (16.0%) | 2 (0.8%) | 52 (21.4%) | 0 |
| Nausea | 27 (11.4%) | 0 | 34 (14.0%) | 2 (0.8%) |
| Vomiting | 9 (3.8%) | 0 | 27 (11.1%) | 0 |
| Abdominal pain upper | 7 (3.0%) | 0 | 18 (7.4%) | 1 (0.4%) |
| Respiratory, thoracic and mediastinal disorders | | | | |
| Cough ^d | 32 (13.5%) | 0 | 73 (30.0%) | 0 |
| Dyspnoea ^e | 26 (11.0%) | 3 (1.3%) | 51 (21.0%) | 10 (4.1%) |
| Bronchospasm | 1 (0.4%) | 0 | 23 (9.5%) | 6 (2.5%) |
| Throat irritation ^f | 1 (0.4%) | 0 | 15 (6.2%) | 0 |
| Epistaxis | 12 (5.1%) | 1 (0.4%) | 13 (5.3%) | 1 (0.4%) |
| Nasal congestion | 3 (1.3%) | 0 | 13 (5.3%) | 1 (0.4%) |
| General disorders and administration site conditions | | | | |
| Oedema peripheral ^g | 32 (13.5%) | 0 | 58 (23.9%) | 2 (0.8%) |
| Fatigue | 58 (24.5%) | 8 (3.4%) | 53 (21.8%) | 12 (4.9%) |
| Pyrexia | 28 (11.8%) | 3 (1.3%) | 42 (17.3%) | 3 (1.2%) |
| Asthenia | 37 (15.6%) | 5 (2.1%) | 24 (9.9%) | 2 (0.8%) |
| Musculoskeletal and connective tissue disorders | | | | |
| Back pain | 24 (10.1%) | 3 (1.3%) | 44 (18.1%) | 5 (2.1%) |
| Arthralgia | 13 (5.5%) | 0 | 29 (11.9%) | 4 (1.6%) |
| Pain in extremity | 16 (6.8%) | 2 (0.8%) | 26 (10.7%) | 4 (1.6%) |
| Muscle spasms | 5 (2.1%) | 0 | 21 (8.6%) | 0 |
| Bone pain | 14 (5.9%) | 3 (1.3%) | 19 (7.8%) | 4 (1.6%) |
| Musculoskeletal chest pain | 5 (2.1%) | 0 | 19 (7.8%) | 1 (0.4%) |
| Musculoskeletal pain | 3 (1.3%) | 0 | 14 (5.8%) | 1 (0.4%) |
| Metabolism and nutrition disorders | | | | |
| Decreased appetite | 12 (5.1%) | 1 (0.4%) | 26 (10.7%) | 2 (0.8%) |
| Hypokalaemia | 11 (4.6%) | 3 (1.3%) | 25 (10.3%) | 6 (2.5%) |
| Hyperglycaemia | 18 (7.6%) | 6 (2.5%) | 22 (9.1%) | 9 (3.7%) |
| Hypocalcaemia | 11 (4.6%) | 2 (0.8%) | 14 (5.8%) | 4 (1.6%) |
| Hypophosphataemia | 7 (3.0%) | 1 (0.4%) | 13 (5.3%) | 5 (2.1%) |
| Psychiatric disorders | | | | |
| Insomnia | 36 (15.2%) | 3 (1.3%) | 42 (17.3%) | 1 (0.4%) |
| Skin and subcutaneous tissue disorders | | | | |

Table 5: Number of Subjects With 1 or More Treatment-emergent Adverse Events ($\geq 5\%$) in patients treated with DVd by MedDRA System-Organ Class, Preferred Term and Toxicity Grade; Safety Analysis Set (Study 54767414MMY3004)

| | MMY3004 | | | |
|--------------------------------------|---------------|---------------|---------------|---------------|
| | Vd (N=237) | | DVd (N=243) | |
| | Any Grade (%) | Grade 3/4 (%) | Any Grade (%) | Grade 3/4 (%) |
| Rash ^h | 8 (3.4%) | 0 | 20 (8.2%) | 0 |
| Vascular disorders | | | | |
| Hypertension ⁱ | 8 (3.4%) | 2 (0.8%) | 22 (9.1%) | 16 (6.6%) |
| Hypotension | 10 (4.2%) | 4 (1.7%) | 13 (5.3%) | 4 (1.6%) |
| Investigations | | | | |
| Alanine aminotransferase increased | 10 (4.2%) | 0 | 17 (7.0%) | 4 (1.6%) |
| Weight decreased | 3 (1.3%) | 0 | 16 (6.6%) | 0 |
| Aspartate aminotransferase increased | 5 (2.1%) | 0 | 13 (5.3%) | 0 |

Key: DVd=Daratumumab-bortezomib-dexamethasone, Vd=bortezomib-dexamethasone.

^a “Upper respiratory tract infection” includes bronchitis, sinusitis, respiratory tract infection viral, rhinitis, pharyngitis, respiratory tract infection, metapneumovirus infection, tracheobronchitis, viral upper respiratory tract infection, laryngitis, respiratory syncytial virus infection, staphylococcal pharyngitis, tonsillitis, viral pharyngitis, acute sinusitis, nasopharyngitis, bronchiolitis, bronchitis viral, pharyngitis streptococcal, tracheitis, upper respiratory tract infection bacterial, bronchitis bacterial, epiglottitis, laryngitis viral, oropharyngeal candidiasis, respiratory moniliasis, viral rhinitis, acute tonsillitis, rhinovirus infection.

^b “Pneumonia” includes lobar pneumonia, pneumonia cytomegaloviral, pneumocystis jirovecii pneumonia, pneumonia pneumococcal, bronchopneumonia, lung infection, pulmonary sepsis, pneumonia legionelle, pneumonia bacterial, pneumonia influenza, pneumonia haemophilus, pneumonia Klebsiella, pneumonia streptococcal, pneumonia aspiration, pneumonia viral

^c “Neutropenia” includes febrile neutropenia

^d “Oedema peripheral” includes oedema, generalised oedema, peripheral swelling

^e “Cough” includes productive cough, allergic cough

^f “Dyspnoea” include dyspnoea exertional

^g “Rash” includes rash erythematous, rash maculo-papular, rash pruritic, rash macular

^h “Hypertension” includes blood pressure increased

Note: Adverse events are reported using MedDRA version 18.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

Less Common Clinical Trial Adverse Events (Study MMY3004)

Other TEAEs ($<5\%$ in the DVd arm) of clinical relevance include:

Infections and infestations: urinary tract infection, influenza, oral herpes, gastroenteritis.

Nervous system disorders: paraesthesia, dysgeusia, peripheral motor neuropathy, lethargy.

Gastrointestinal disorders: abdominal distension, abdominal pain, abdominal discomfort, gastroesophageal reflux disease, dyspepsia.

General disorders and administration site conditions: chills, pain, chest pain, influenza-like illness, injection site erythema, malaise.

Respiratory, thoracic and mediastinal disorders: epistaxis, nasal congestion, oropharyngeal pain, rhinorrhea, wheezing.

Musculoskeletal and connective tissue disorders: musculoskeletal pain, myalgia, myopathy, spinal pain, neck pain.

Metabolism and nutritional disorders: hypocalcemia, hyponatremia, hypoalbuminemia diabetes mellitus, hypercalcemia.

Psychiatric disorders: depression, restlessness.

Vascular disorders: hypotension, flushing, hematoma.

Investigations: aspartate aminotransferase increased, glutamyltransferase increased, weight increased, blood creatinine increased.

Skin and subcutaneous tissue disorders: hyperhidrosis, erythema, pruritis.

Eye disorders: eye irritation, lacrimation increased, dry eye, vision blurred.

Cardiac disorders: atrial fibrillation, sinus tachycardia, palpitations.

Injury, poisoning and procedural complications: fall.

Ear and labyrinth disorders: vertigo, tinnitus.

Renal and urinary disorders: renal impairment.

Endocrine disorders: cushingoid.

Abnormal Hematologic and Clinical Chemistry Findings (Study MMY3004)

Laboratory abnormalities worsening during treatment from baseline are listed in Table 6.

Table 6: Treatment-emergent hematology laboratory abnormalities in Study MMY3004

| | Study MMY3004 | | | | | |
|------------------|----------------------|---------|---------|---------------------|---------|---------|
| | DVd (N=243) n (%) | | | Vd (N=237) n (%) | | |
| | Any Grade | Grade 3 | Grade 4 | Any Grade | Grade 3 | Grade 4 |
| Anemia | 122 (50) | 35 (14) | 0 | 133 (56) | 33 (14) | 0 |
| Thrombocytopenia | 218 (90) | 68 (28) | 48 (20) | 202 (85) | 52 (22) | 31 (13) |
| Neutropenia | 147 (60) | 28 (12) | 11 (5) | 95 (40) | 14 (6) | 1 (<1) |
| Lymphopenia | 216 (89) | 99 (41) | 18 (7) | 192 (81) | 57 (24) | 8 (3) |

Key: D=Daratumumab, Vd=bortezomib-dexamethasone.

The incidence of Grade 3 or 4 febrile neutropenia was 2% (DVd) and 0.4% (Vd). The incidence of all grade bleeding events was 14% (DVd) and 11% (Vd), and serious bleeding events were 2.1% (DVd) and 1.3% (Vd).

Patients with multiple myeloma who have received at least three prior lines of therapy including a PI and an IMiD, or who are refractory to both a PI and an IMiD

TEAEs occurring at a rate of $\geq 2\%$ are presented in Table 7.

Table 7: Treatment-emergent adverse events (≥ 2%) in multiple myeloma patients treated with DARZALEX® 16 mg/kg

| | All Grades n (%) N= 156 | Grades 3-4 n (%) N= 156 |
|--|-------------------------------|-------------------------------|
| General disorders and administration site conditions | | |
| Fatigue | 62 (39.7%) | 3 (1.9%) |
| Pyrexia | 34 (21.8%) | 2 (1.3%) |
| Chills | 16 (10.3%) | 0 |
| Asthenia | 13 (8.3%) | 1 (0.6%) |
| Oedema peripheral | 11 (7.1%) | 1 (0.6%) |
| Chest pain | 9 (5.8%) | 0 |
| Pain | 8 (5.1%) | 1 (0.6%) |
| Influenza like illness | 7 (4.5%) | 1 (0.6%) |
| Non-cardiac chest pain | 7 (4.5%) | 0 |
| General physical health deterioration | 5 (3.2%) | 1 (0.6%) |
| Chest discomfort | 4 (2.6%) | 0 |
| Respiratory, thoracic and mediastinal disorders | | |
| Cough | 38 (24.4%) | 0 |
| Nasal congestion | 29 (18.6%) | 0 |
| Dyspnoea | 25 (16.0%) | 1 (0.6%) |
| Oropharyngeal pain | 15 (9.6%) | 0 |
| Rhinitis allergic | 11 (7.1%) | 0 |
| Throat irritation | 10 (6.4%) | 0 |
| Dyspnoea exertional | 9 (5.8%) | 0 |
| Epistaxis | 9 (5.8%) | 0 |
| Productive cough | 8 (5.1%) | 0 |
| Wheezing | 8 (5.1%) | 0 |
| Bronchospasm | 5 (3.2%) | 2 (1.3%) |
| Pleural effusion | 4 (2.6%) | 0 |
| Sinus congestion | 4 (2.6%) | 0 |
| Sneezing | 4 (2.6%) | 0 |
| Musculoskeletal and connective tissue disorders | | |
| Back pain | 40 (25.6%) | 4 (2.6%) |
| Arthralgia | 28 (17.9%) | 0 |
| Pain in extremity | 26 (16.7%) | 1 (0.6%) |
| Musculoskeletal chest pain | 19 (12.2%) | 2 (1.3%) |
| Musculoskeletal pain | 16 (10.3%) | 1 (0.6%) |
| Bone pain | 15 (9.6%) | 1 (0.6%) |
| Muscle spasms | 10 (6.4%) | 0 |
| Myalgia | 7 (4.5%) | 0 |
| Neck pain | 5 (3.2%) | 2 (1.3%) |
| Groin pain | 4 (2.6%) | 1 (0.6%) |
| Infections and infestations | | |
| Upper respiratory tract infection ^a | 63 (40.4%) | 12 (7.7%) |
| Nasopharyngitis ^b | 25 (16.0%) | 0 |
| Pneumonia ^c | 17 (10.9%) | 9 (5.8%) |
| Sinusitis ^b | 11 (7.1%) | 0 |
| Urinary tract infection | 9 (5.8%) | 0 |
| Bronchitis ^b | 8 (5.1%) | 1 (0.6%) |
| Herpes zoster | 5 (3.2%) | 2 (1.3%) |
| Influenza | 4 (2.6%) | 0 |

Table 7: Treatment-emergent adverse events (≥ 2%) in multiple myeloma patients treated with DARZALEX® 16 mg/kg

| | All Grades n (%) N= 156 | Grades 3-4 n (%) N= 156 |
|--|-------------------------------|-------------------------------|
| Gastrointestinal disorders | | |
| Nausea | 44 (28.2%) | 0 |
| Diarrhoea | 28 (17.9%) | 1 (0.6%) |
| Constipation | 24 (15.4%) | 0 |
| Vomiting | 21 (13.5%) | 0 |
| Abdominal pain | 9 (5.8%) | 2 (1.3%) |
| Abdominal discomfort | 4 (2.6%) | 0 |
| Dyspepsia | 4 (2.6%) | 0 |
| Stomatitis | 4 (2.6%) | 0 |
| Toothache | 4 (2.6%) | 0 |
| Blood and lymphatic system disorders | | |
| Anaemia | 43 (27.6%) | 27 (17.3%) |
| Neutropenia | 36 (23.1%) | 19 (12.2%) |
| Thrombocytopenia | 32 (20.5%) | 22 (14.1%) |
| Leukopenia | 15 (9.6%) | 7 (4.5%) |
| Lymphopenia | 10 (6.4%) | 9 (5.8%) |
| Metabolism and nutrition disorders | | |
| Decreased appetite | 23 (14.7%) | 1 (0.6%) |
| Hypercalcaemia | 18 (11.5%) | 5 (3.2%) |
| Hyperglycaemia | 14 (9.0%) | 4 (2.6%) |
| Hypokalaemia | 12 (7.7%) | 1 (0.6%) |
| Hypomagnesaemia | 10 (6.4%) | 0 |
| Hyponatraemia | 8 (5.1%) | 0 |
| Hyperkalaemia | 5 (3.2%) | 1 (0.6%) |
| Hypoalbuminaemia | 5 (3.2%) | 0 |
| Hyperuricaemia | 4 (2.6%) | 1 (0.6%) |
| Nervous system disorders | | |
| Headache | 19 (12.2%) | 2 (1.3%) |
| Dizziness | 14 (9.0%) | 0 |
| Hypoaesthesia | 8 (5.1%) | 0 |
| Peripheral sensory neuropathy | 7 (4.5%) | 0 |
| Somnolence | 5 (3.2%) | 1 (0.6%) |
| Tremor | 4 (2.6%) | 0 |
| Investigations | | |
| Blood creatinine increased | 10 (6.4%) | 2 (1.3%) |
| Weight decreased | 8 (5.1%) | 1 (0.6%) |
| Aspartate aminotransferase increased | 6 (3.8%) | 0 |
| Alanine aminotransferase increased | 4 (2.6%) | 1 (0.6%) |
| Blood alkaline phosphatase increased | 4 (2.6%) | 0 |
| Weight increased | 4 (2.6%) | 0 |
| Skin and subcutaneous tissue disorders | | |
| Pruritus | 5 (3.2%) | 0 |
| Dry skin | 4 (2.6%) | 0 |
| Hyperhidrosis | 4 (2.6%) | 0 |
| Rash | 4 (2.6%) | 0 |
| Injury, poisoning and procedural complications | | |
| Contusion | 5 (3.2%) | 0 |

Table 7: Treatment-emergent adverse events ($\geq 2\%$) in multiple myeloma patients treated with DARZALEX[®] 16 mg/kg

| | All Grades n (%) N= 156 | Grades 3-4 n (%) N= 156 |
|---|-------------------------------|-------------------------------|
| Fall | 5 (3.2%) | 1 (0.6%) |
| Rib fracture | 4 (2.6%) | 0 |
| Psychiatric disorders | | |
| Anxiety | 10 (6.4%) | 0 |
| Insomnia | 9 (5.8%) | 0 |
| Confusional state | 8 (5.1%) | 2 (1.3%) |
| Vascular disorders | | |
| Hypertension | 15 (9.6%) | 7 (4.5%) |
| Hypotension | 7 (4.5%) | 1 (0.6%) |
| Flushing | 4 (2.6%) | 0 |
| Haematoma | 4 (2.6%) | 0 |
| Eye disorders | | |
| Vision blurred | 10 (6.4%) | 0 |
| Renal and urinary disorders | | |
| Dysuria | 4 (2.6%) | 0 |
| Cardiac disorders | | |
| Palpitations | 5 (3.2%) | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | |
| Basal cell carcinoma | 4 (2.6%) | 0 |

^a includes upper respiratory tract infection, nasopharyngitis, sinusitis, bronchitis, pharyngitis, rhinitis, viral upper respiratory tract infection, respiratory tract infection, lower respiratory tract infection, pneumonia, lobar pneumonia, and pneumonia streptococcal.

^b includes upper respiratory tract infection, nasopharyngitis, sinusitis, bronchitis, pharyngitis, rhinitis, viral upper respiratory tract infection, and respiratory tract infection.

^c includes pneumonia, lobar pneumonia, and pneumonia streptococcal.

There were 4 deaths due to TEAEs (cardio-respiratory arrest [n=1], pneumonia [n=2] and general physical health deterioration [n=1]).

Bleeding events occurred in 20 patients (18.9%) in study MMY2002 and 2 patients (4.4%) in study GEN501. These were mainly Grade 1/2, with two Grade 3 events. Of these patients, 9 patients also had thrombocytopenia.

Less Common Clinical Trial Adverse Events

Other TEAEs (<2%) of clinical relevance not meeting the threshold in Table 5 include:

Blood and lymphatic system disorders: red blood cell agglutination, crossmatch incompatible.

Respiratory, thoracic and mediastinal disorders: hypoxia, throat tightness, upper-airway cough syndrome, respiratory failure, dysphonia, laryngeal edema, laryngitis allergic, pulmonary edema, rhinorrhea.

Gastrointestinal disorders: abdominal distension, gastroesophageal reflux disease, colitis, dysphagia, gastritis, pancreatitis.

Infections and infestations: conjunctivitis, candida infection, varicella, cellulitis, cystitis, ear infection, gastroenteritis, oral fungal infection, pyelonephritis, parainfluenza virus infection, pharyngitis, sepsis.

Metabolism and nutrition disorders: hypocalcemia; diabetes mellitus, hypernatremia, hyperphosphatemia, hypoglycemia.

Nervous system disorders: syncope, depressed level of consciousness, encephalopathy.

Skin and subcutaneous tissue disorders: eczema, erythema, petechia, rash maculo-papular, urticaria.

Vascular disorders: flushing.

Renal and urinary disorders: hematuria, pollakiuria, proteinuria, renal failure, urinary retention.

Investigations: electrocardiogram QT prolonged.

Cardiac disorders: tachycardia, angina pectoris, atrial flutter, bradycardia, cardiac failure congestive, transient ischemic attack.

Immune system disorders: allergic edema, cytokine release syndrome, seasonal allergy.

Abnormal Hematologic and Clinical Chemistry Findings

Laboratory parameters with treatment-emergent worsening toxicity grade ($\geq 20\%$) during treatment are presented in Table 8.

Table 8: Laboratory hematology and chemistry treatment-emergent worsening toxicity grade during treatment (incidence $\geq 20\%$) in multiple myeloma patients treated with DARZALEX[®] 16 mg/kg (n=156)

| | Toxicity Grade | | |
|------------------------|----------------|------------|-----------|
| | Any Grade | 3 | 4 |
| Hematology | | | |
| WBC low | 89 (57.1%) | 26 (16.7%) | 3 (1.9%) |
| Hemoglobin low | 70 (44.9%) | 30 (19.2%) | 0 |
| Platelets low | 75 (48.4%) | 15 (9.7%) | 13 (8.4%) |
| Neutrophils low | 93 (59.6%) | 26 (16.7%) | 5 (3.2%) |
| Lymphocytes low | 113 (72.4%) | 46 (29.5%) | 15 (9.6%) |
| Chemistry | | | |
| AST high | 35 (23.3%) | 2 (1.3%) | 0 |
| Creatinine high | 33 (21.7%) | 3 (2.0%) | 0 |
| Sodium low | 45 (29.6%) | 6 (4.0%) | 0 |
| Potassium low | 32 (21.1%) | 4 (2.6%) | 1 (0.7%) |
| Corrected calcium high | 49 (32.2%) | 6 (3.9%) | 5 (3.3%) |
| Corrected calcium low | 48 (31.6%) | 0 | 0 |
| Albumin low | 62 (40.8%) | 5 (3.3%) | 0 |

Keys: WBC = White Blood Cell.

Note: The laboratory toxicity grades are derived based on the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) Version 4.03.

Note: For each lab parameter, percentages are calculated with denominator as the number of subjects with both a baseline and postbaseline laboratory value available. Only subjects with worsening toxicity grade during treatment compared to baseline are reported.

Ten subjects (6%) received granulocyte-colony stimulating factor. No treatment-emergent adverse events of febrile neutropenia were reported. Forty-six subjects (29.5%) received a red blood cell transfusion (37.7% in the MMY2002 study and 11.1% in the GEN501 study). No treatment-emergent adverse events related to red blood cell transfusions were reported.

Infusion-related Reactions (IRRs)

In clinical trials (monotherapy and combination treatments, n=1063), the majority of IRRs were Grades 1 and 2. Grade 3 and Grade 4 IRRs were reported in 5.4% and 0.2% of patients, respectively. The incidence of any grade infusion-related reactions was 39% with the first (16 mg/kg, Week 1) infusion of DARZALEX[®], 2% with the Week 2 infusion, and 4% with subsequent infusions. Less than 1% of patients had a Grade ≥ 3 infusion reaction with Week 2 or subsequent infusions. The median time to onset of a reaction was 1.5 hours (range: 0.0 to 72.8 hours). The incidence of infusion modifications due to reactions was 36.3%. Median durations of 16 mg/kg infusions for the 1st, 2nd and subsequent infusions were 6.9, 4.2 and 3.4 hours respectively. Discontinuation of daratumumab treatment due to an IRR occurred in <1% of patients.

IRRs include, but are not limited to, the following adverse reaction terms: cough, dyspnea, chills, (all $\geq 5\%$), bronchospasm (4.7%), throat irritation (4.0%), nasal congestion (3.8%), nausea (3.7%), hypertension (3.1%), allergic rhinitis (2.1%), and hypoxia (0.9%). Severe IRRs (5.6%)

included hypertension, dyspnea (both 1.5%), bronchospasm (1.1%), laryngeal edema (0.6%), hypoxia (0.5%), and pulmonary edema (0.1%).

In phase 1b Study MMY1001 (n=97), patients were given daratumumab in combination treatments with the first dose at Week 1 split over two days (i.e. 8 mg/kg on Day 1 and 8 mg/kg on Day 2). Interim study results demonstrate that 42% of patients had an IRR (any grade), with 35 (36%) patients experiencing IRRs on Day 1 of Week 1, 4 (4%) patients on Day 2 of Week 1, and 8 (8%) patients with subsequent infusions. The median time to onset of a reaction was 1.8 hours (range: 0.1 to 5.4 hours). The incidence of infusion interruptions due to reactions was 30%. Median durations of infusions were 4.2 h for the Week 1-Day 1, 4.2 h for Week 1-Day 2, and 3.4 hours for the subsequent infusions.

Infections

In DARZALEX[®] 16 mg/kg monotherapy studies, infections were reported in 59% of patients, the majority were respiratory tract infections (including upper respiratory tract infections and pneumonia) (48.1%). Most infections were Grade 1/2 in severity and Grade 3/4 infections were reported in 10% of patients. Pneumonia was the most common Grade 3/4 infection (5.8%).

Opportunistic infections were observed in 10.9% of the patients. Opportunistic infections occurred at a higher incidence in patients receiving DVd (14%) compared to Vd alone (9%). Grade 3 and 4 TEAEs of opportunistic infection occurred in 5% of patients in the DVd arm and 0.4% of patients in the Vd arm. The incidence of opportunistic infections (any grade) was 13.1% in the DRd arm compared with 11.4% in the Rd arm. Serious opportunistic infection occurred in 2.5% of patients in the DRd arm and in 1.4% of patients in the Rd arm.

In DARZALEX[®] combination therapy studies for patients with relapsed or refractory multiple myeloma, infections were reported in 87% and 73% of patients in the DRd and DVd groups, respectively. Grade 1 or 2 infections were reported with DARZALEX[®] combinations and background therapies (Grade 1 - DVd: 7.8%, Vd: 10%, DRd: 14.1%, Rd: 10.7%; Grade 2 – DVd: 39.1%, Vd: 24.9%, DRd: 41.0%, Rd: 39.5%). Grade 3 or 4 infections were reported with DARZALEX[®] combinations and background therapies (DVd: 26%, Vd: 19%, DRd: 31%, Rd: 24%). Grade 5 infections were also reported (DVd: 1.2%, Vd: 1.7%, DRd: 2.8%, Rd: 1.4%). Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. Discontinuations from treatment due to infection were reported (DVd: 4.1%, Vd: 2.5%, DRd: 4.6%, Rd: 2.5%). Fatal infections were reported in 0.8% to 2% of patients across studies primarily due to pneumonia and sepsis.

In the DARZALEX[®] combination therapy study for patients with newly diagnosed multiple myeloma, infections were reported in 67% and 48% of patients in the D-VMP and VMP groups, respectively. Grade 3 or 4 infections were reported in 23% (D-VMP) and 15% (VMP) of patients. Discontinuations from treatment due to infection were reported (D-VMP: 0.9%, VMP: 1.4%). Fatal infections were reported in 1.4% of patients treated with D-VMP due to pneumonia, sepsis, peritonitis, or upper respiratory tract infection.

Herpes Zoster Virus Reactivation

In DARZALEX[®] 16 mg/kg monotherapy studies, systemic anti-viral medications were used in 75% of patients. Herpes zoster was reported in 3% of patients.

In DARZALEX[®] combination studies for patients with relapsed or refractory multiple myeloma, systemic anti-viral medications were used in 59% of patients. Herpes zoster was reported in 3.3% of patients. In the DARZALEX[®] combination study for patients with newly diagnosed multiple myeloma, systemic anti-viral medications were used in 80% of patients. Herpes zoster was reported in 4.6% of patients.

Cardiac Disorders

In DARZALEX[®] combination therapy studies, a higher incidence of all grade cardiac TEAEs occurred in the DARZALEX[®] arm compared with the control arm: in study MMY3003 (DRd: 16.3% vs Rd: 10.0%); in study MMY3004 (DVd: 14.0% vs Vd: 6.3%); and in study MMY3007 (D-VMP: 14.7% vs VMP: 11.3%). Grade 3 and 4 cardiac TEAEs were generally balanced between the 2 arms in the studies (DRd: 3.9% vs Rd: 3.2%; DVd: 4.5% vs Vd: 3.0%; D-VMP: 3.8% vs VMP: 3.1%).

In study MMY3004, the most commonly reported cardiac disorder TEAEs in the DVd arm were atrial fibrillation (DVd 4.5%; Vd 1.7%), sinus tachycardia (DVd 2.5%; Vd 0.4%), and palpitations (DVd 2.1%; Vd 0.8%). Deaths due to cardiac disorders occurred in 1.2% of patients in the DVd arm and 0.4% of patients in the Vd arm.

In study MMY3003, the most commonly reported cardiac disorder TEAEs in the DRd arm were atrial fibrillation (DRd 3.5%; Rd 2.8%), tachycardia (DRd 3.5%; Rd 0.7%), and angina pectoris (DRd 2.8%; Rd 0.4%).

In study MMY3007, the most commonly reported cardiac TEAE ($\geq 2\%$ incidence vs VMP arm) was atrial fibrillation (D-VMP: 4.9%; VMP: 2.0%).

Immunogenicity

Patients in DARZALEX[®] monotherapy study MMY2002 (n=111) and combination therapy studies (n=353) were evaluated for anti-therapeutic antibody (ATA) responses to daratumumab at multiple time points during treatment and up to 8 weeks following the end of treatment using an electrochemiluminescent (ECL) assay. Following the start of daratumumab dosing, of the 464 evaluable patients, none of the monotherapy patients and 2 (0.4%) of the combination therapy patients tested positive for anti-daratumumab antibodies; 1 of the combination therapy patients developed transient neutralizing antibodies against daratumumab. However, the immunogenicity assay used in the study has limitations in detecting anti-daratumumab antibodies in the presence of high concentrations of daratumumab; therefore, the incidence of antibody development might not have been reliably determined.

Immunogenicity data are highly dependent on the sensitivity and specificity of the test methods used. Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, drug interference, concomitant medication and the underlying disease. Therefore, comparison of the incidence of antibodies to daratumumab with the incidence of antibodies to other products may be misleading.

Post-Market Adverse Drug Reactions

The following adverse reactions have been reported during post-marketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.

Immune system disorders: anaphylactic reaction (see **WARNINGS AND PRECAUTIONS – Infusion-Related Reactions**)

Infections and infestations: hepatitis B virus reactivation

DRUG INTERACTIONS

Overview

No formal drug interaction studies have been conducted with daratumumab.

Interference with Indirect Antiglobulin Tests (Coombs Test)

Daratumumab binds to CD38 on RBCs and interferes with compatibility testing, including antibody screening and cross matching. Daratumumab interference mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to disrupt daratumumab binding or genotyping. Since the Kell blood group system is also sensitive to DTT treatment, K-negative units should be supplied after ruling out or identifying alloantibodies using DTT-treated RBCs.

If an emergency transfusion is required, non-cross-matched ABO/RhD-compatible RBCs can be given per local practices.

Interference with Serum Protein Electrophoresis and Immunofixation Tests

Daratumumab may be detected on serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for monitoring disease monoclonal immunoglobulins (M protein). This can lead to false positive SPE and IFE assay results for patients with IgG kappa myeloma protein impacting initial assessment of complete responses by International Myeloma Working Group (IMWG) criteria. In patients with persistent very good partial response, consider other methods to evaluate the depth of response.

Drug-Drug Interactions

No formal drug-drug interaction studies have been conducted with daratumumab. IgG1 molecules are biotransformed by degradation into small peptides and amino acids via catabolic pathways.

Drug-Food Interactions

No formal drug-food interaction studies have been conducted with daratumumab.

Drug-Herb Interactions

No formal drug-herb interaction studies have been conducted with daratumumab.

Drug-Laboratory Interactions

No formal drug-laboratory studies have been conducted with daratumumab.

DOSAGE AND ADMINISTRATION

Dosing Considerations

- DARZALEX[®] should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion-related reactions if they occur.
- Pre- and post-infusion medications should be administered (see [Recommended Concomitant Medications](#)).
- Administer only as an intravenous infusion after dilution (see [Administration](#)).

Recommended Dose

Newly Diagnosed Multiple Myeloma

Combination therapy with bortezomib, melphalan and prednisone (6-week cycle dosing regimens) for patients ineligible for autologous stem cell transplant

The recommended dose of DARZALEX[®] is 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 9.

Table 9: DARZALEX[®] dosing schedule in combination with bortezomib, melphalan and prednisone (VMP); 6-week cycle dosing regimen)

| Weeks | Schedule |
|--|---------------------------------------|
| Weeks 1 to 6 | weekly (total of 6 doses) |
| Weeks 7 to 54 ^a | every three weeks (total of 16 doses) |
| Week 55 onwards until disease progression ^b | every four weeks |

^a First dose of the every-3-week dosing schedule is given at Week 7

^b First dose of the every-4-week dosing schedule is given at Week 55

Bortezomib is given twice weekly at Weeks 1, 2, 4 and 5 for the first 6-week cycle, followed by once weekly at Weeks 1, 2, 4 and 5 for eight more 6-week cycles. Melphalan (9 mg/m²) and prednisone (60 mg/m²) are given on days 1-4 of each cycle. For more information on the VMP dose and dosing schedule when administered with DARZALEX[®], see the **CLINICAL TRIALS** section.

Relapsed/Refractory Multiple Myeloma

Monotherapy and Combination therapy with lenalidomide/dexamethasone (4-week cycle regimens)

The recommended dose of DARZALEX[®] is 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule (Table 10):

Table 10: Dosing schedule for DARZALEX[®] monotherapy and in combination with lenalidomide/dexamethasone (4-week cycle dosing regimens)

| Weeks | Schedule |
|--|------------------------------------|
| Weeks 1 to 8 | weekly (total of 8 doses) |
| Weeks 9 to 24 ^a | every two weeks (total of 8 doses) |
| Week 25 onwards until disease progression ^b | every four weeks |

^a First dose of the every 2-week-dosing schedule is given at Week 9

^b First dose of the every 4-week-dosing schedule is given at Week 25

For dosing instructions for medicinal products administered with DARZALEX[®], see the **CLINICAL TRIALS** section, and consult the corresponding Product Monographs.

Combination therapy with bortezomib/dexamethasone (3-week cycle regimens)

The recommended dose of DARZALEX[®] is 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule (Table 11):

Table 11: Dosing schedule for DARZALEX[®] with bortezomib/dexamethasone (3-week cycle dosing regimens)

| Weeks | Schedule |
|--|--------------------------------------|
| Weeks 1 to 9 | weekly (total of 9 doses) |
| Weeks 10 to 24 ^a | every three weeks (total of 5 doses) |
| Week 25 onwards until disease progression ^b | every four weeks |

^a First dose of the every 3-week dosing schedule is given at Week 10

^b First dose of the every 4-week dosing schedule is given at Week 25

For dosing instructions for medicinal products administered with DARZALEX[®], see the **CLINICAL TRIALS** section, and consult the corresponding Product Monographs.

Missed Dose

If a planned dose of DARZALEX[®] is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly, maintaining the treatment interval.

Dose modifications

No dose reductions of DARZALEX[®] are recommended. Dose delay may be required to allow recovery of blood cell counts in the event of hematological toxicity (see **WARNINGS AND PRECAUTIONS**). For information concerning medicinal products given in combination with DARZALEX[®], consult the corresponding Product Monographs.

Administration

It is very important that the instructions for preparation and administration provided in this section are strictly followed to minimize medication errors.

DARZALEX[®] is administered as an intravenous infusion following dilution with 0.9% Sodium Chloride. Following dilution the DARZALEX[®] infusion should be intravenously administered at the appropriate initial infusion rate with incremental escalation as presented in Table 12.

For subsequent infusions, incremental escalation of the starting infusion rate or reduction in dilution volume should be considered only in the absence of infusion reactions (see Table 12).

To facilitate administration, the first 16 mg/kg dose at Week 1 may be split over two consecutive days, i.e. 8 mg/kg on Day 1 and 8 mg/kg on Day 2 (see Table 12 below).

Table 12: Infusion rates for DARZALEX[®] administration

| | Dilution volume | Initial rate (first hour) | Rate Increment^a | Maximum rate |
|--|------------------------|----------------------------------|-----------------------------------|---------------------|
| Week 1 Infusion | | | | |
| <i>Option 1 (Single dose infusion)</i> | | | | |
| Week 1 (16 mg/kg) | 1000 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
| <i>Option 2 (Split dose infusion)</i> | | | | |
| Week 1 Day 1 (8 mg/kg) | 500 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
| Week 1 Day 2 (8 mg/kg) | 500 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
| Week 2 (16 mg/kg) Infusion^b | 500 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
| Subsequent (Week 3 onwards, 16 mg/kg) Infusions^c | 500 mL | 100 mL/hour | 50 mL/hour every hour | 200 mL/hour |

^a Consider incremental escalation of the infusion rate only in the absence of infusion reactions (see Table 13).

^b Dilution volume of 500 mL for the 16 mg/kg dose should be used only if there were no infusion reactions the previous week. Otherwise, use a dilution volume of 1000 mL.

^c Use a modified initial rate (100 mL/hour) for subsequent infusions (i.e. Week 3 onwards) only if there were no infusion reactions during a final infusion rate of ≥ 100 mL/hour in the Week 1 and Week 2 infusions. Otherwise, continue to use instructions indicated in the table for the Week 2 infusion rate.

Management of infusion-related reactions

Administer pre-infusion medications prior to treatment with DARZALEX[®] to reduce the risk of infusion-related reactions.

For infusion-related reactions of any grade/severity, immediately interrupt the DARZALEX[®] infusion, and manage symptoms.

Management of infusion-related reactions may require reduction in the rate of infusion, or treatment discontinuation of DARZALEX[®] as outlined in Table 13 (see **WARNINGS AND PRECAUTIONS**).

Table 13: Infusion Rate Modification Guidelines for Infusion-Related Reactions

| Infusion-Related Reaction Grade | Infusion Rate Modification |
|--|--|
| Grade 1-2 (mild to moderate) | Temporarily interrupt infusion and treat symptoms. Once the patient's condition is stable and the reaction symptoms resolve, resume the infusion at no more than half the rate at which the reaction occurred. If the patient does not experience any further infusion-related reaction symptoms, infusion rate escalation may resume at increments and intervals as clinically appropriate up to the maximum rate of 200 mL/hour (see Table 12). |
| Grade 3 (severe) | Temporarily interrupt infusion and treat symptoms. Once reaction symptoms resolve, consider restarting the infusion at no more than half the rate at which the reaction occurred. If the patient does not experience additional symptoms, resume infusion rate escalation at increments and intervals as appropriate (see Table 12). Repeat the procedure above in the event of recurrence of Grade 3 symptoms. Permanently discontinue DARZALEX [®] upon the third occurrence of a Grade 3 or greater infusion reaction. |
| Grade 4 (life threatening) | Permanently discontinue DARZALEX [®] treatment. |

Recommended Concomitant Medications*Pre-infusion medication*

For all patients, to reduce the risk of infusion-related reactions administer pre-infusion medications approximately 1-3 hours prior to every infusion of DARZALEX[®] as follows:

Monotherapy:

- intravenous corticosteroid (methylprednisolone 100 mg, or equivalent dose of an intermediate-acting or long-acting corticosteroid) plus
- oral antipyretics (acetaminophen 650 to 1000 mg), plus
- oral or intravenous antihistamine (diphenhydramine 25 to 50 mg or equivalent).

Following the second infusion, the dose of corticosteroid may be reduced (e.g., methylprednisolone 60 mg IV).

Combination therapy:

- Administer 20 mg dexamethasone (or equivalent) prior to every DARZALEX[®] infusion (see **CLINICAL TRIALS**).
- Dexamethasone is given intravenously prior to the first DARZALEX[®] infusion and oral administration may be considered prior to subsequent infusions. Additional background

regimen specific corticosteroids (e.g. prednisone) should not be taken on DARZALEX[®] infusion days when patients have received dexamethasone as a pre-medication.

- Antipyretics (oral paracetamol/acetaminophen 650 to 1000 mg).
- Antihistamine (oral or intravenous diphenhydramine 25 to 50 mg or equivalent).

Post-infusion medication:

Administer post-infusion medication to reduce the risk of delayed infusion reactions as follows:

Monotherapy:

- Administer oral corticosteroid (20 mg methylprednisolone or equivalent dose of a corticosteroid (intermediate or long-acting) in accordance with local standards) to patients the first and second day after each infusion (beginning the day after the infusion).

Combination therapy:

- Consider administering low-dose oral methylprednisolone (≤ 20 mg) or equivalent the day after the DARZALEX[®] infusion.
 - However, if a background regimen-specific corticosteroid (e.g. dexamethasone or prednisone) is administered the day after the DARZALEX[®] infusion, additional post-infusion medications may not be needed (see **CLINICAL TRIALS**).

Additionally, for patients with a history of chronic obstructive pulmonary disease, consider the use of post-infusion medications including bronchodilators (short and long acting), and inhaled corticosteroids. Following the first four infusions, if the patient experiences no major infusion-related reactions, these inhaled post-infusion medications may be discontinued.

Prophylaxis for herpes zoster virus reactivation

Anti-viral prophylaxis should be considered for the prevention of herpes zoster virus reactivation.

Instructions for Use and Handling and Disposal

The DARZALEX[®] vial is for single use only.

Prepare the solution for infusion using aseptic technique as follows:

- Calculate the dose (mg), total volume (mL) of DARZALEX[®] solution required and the number of DARZALEX[®] vials needed based on patient weight.
- Check that the DARZALEX[®] solution is colourless to yellow. Do not use if opaque particles, discoloration or other foreign particles are present.
- Using aseptic technique, remove a volume of 0.9% Sodium Chloride solution from the infusion bag/container that is equal to the required volume of DARZALEX[®] solution.
- Withdraw the necessary amount of DARZALEX[®] solution from the vials and dilute to the appropriate volume by adding to an infusion bag/container containing 0.9% Sodium Chloride. Infusion bags/containers must be made of polyvinylchloride (PVC), polypropylene (PP), polyethylene (PE) or polyolefin blend (PP+PE).
- Dilute under appropriate aseptic conditions.
- Discard any unused portion left in the vial.

- Gently invert the bag/container to mix the solution. Do not shake or freeze.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The diluted solution may develop very small, translucent to white proteinaceous particles, as daratumumab is a protein. Do not use if visibly opaque particles, discoloration or foreign particles are observed.
- Since DARZALEX[®] does not contain a preservative, diluted solutions should be used within 15 hours (including infusion time) when kept at room temperature (15°C–25°C) and in room light.
- If not used immediately, the diluted solution can be stored prior to administration for up to 24 hours at refrigerated conditions (2°C–8°C) and protected from light. Do not freeze.
- Administer the diluted solution by intravenous infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, non-pyrogenic, low protein-binding polyethersulfone (PES) filter (pore size 0.22 or 0.2 micrometre). Polyurethane (PU), polybutadiene (PBD), PVC, PP or PE administration sets must be used.
- Do not infuse DARZALEX[®] concomitantly in the same intravenous line with other agents.
- Do not store any unused portion of the infusion solution for reuse. Any unused product or waste material should be disposed of in accordance with local requirements.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

There is no information on overdosage with DARZALEX[®].

There is no known specific antidote for daratumumab overdose. In the event of an overdose, the patient should be monitored for any signs or symptoms of adverse effects and appropriate symptomatic treatment be instituted immediately.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Daratumumab is an IgG1κ human monoclonal antibody (mAb) that targets the CD38 protein expressed at a high level on the surface of cells in a variety of hematological malignancies, including multiple myeloma tumor cells, as well as other cell types and tissues at various levels. CD38 protein has multiple functions such as receptor mediated adhesion, signaling and enzymatic activity.

Daratumumab has been shown to potently inhibit the *in vivo* growth of CD38-expressing tumor cells. Based on *in vitro* studies, daratumumab may utilize multiple effector functions, resulting in immune mediated tumor cell death. These studies suggest that daratumumab can induce tumor cell lysis through multifactorial effects such as activation of complement cascade, i.e. complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity

(ADCC), and antibody-dependent cellular phagocytosis (ADCP) in malignancies expressing CD38.

Daratumumab induced apoptosis in vitro after Fc mediated cross linking. In addition, daratumumab modulated CD38 enzymatic activity, inhibiting the cyclase enzyme activity and stimulating the hydrolase activity. The significance of these in vitro effects in a clinical setting, and the implications on tumor growth, are not well understood.

A subset of myeloid derived suppressor cells (CD38+MDSCs), regulatory T cells (CD38+T_{regs}) and B cells (CD38+B_{regs}) are decreased by daratumumab. T cells (CD3+, CD4+, and CD8+) are also known to express CD38 depending on the stage of development and the level of activation. Significant increases in CD4+ and CD8+ T cell absolute counts, and percentages of lymphocytes, were observed with daratumumab treatment in peripheral whole blood and bone marrow. In addition, T-cell receptor DNA sequencing verified that T-cell clonality was increased with daratumumab treatment, indicating immunomodulatory effects that may contribute to clinical response.

Pharmacodynamics

Natural killer (NK) cell count

NK cells are known to express high levels of CD38 and are susceptible to daratumumab mediated cell lysis. Decreases in absolute counts and percentages of total NK cells (CD16+CD56+) and activated (CD16+CD56^{dim}) NK cells in peripheral whole blood and bone marrow were observed with daratumumab treatment.

Pharmacokinetics

The pharmacokinetics (PK) of daratumumab following intravenous administration of DARZALEX[®] monotherapy were evaluated in patients with relapsed and refractory multiple myeloma at dose levels from 0.1 mg/kg to 24 mg/kg. A population PK model of daratumumab was developed to describe the pharmacokinetic characteristics of daratumumab and to evaluate the influence of covariates on the disposition of daratumumab in patients with multiple myeloma. The population PK analysis included 223 patients receiving DARZALEX[®] monotherapy in two clinical trials (150 subjects received 16 mg/kg). The structural model was comprised of two compartments with parallel linear and Michaelis-Menten elimination from the central compartment. V_{max} was assumed to decrease with time through a K_{des} parameter which had an eta shrinkage of 40%. The other estimated parameters had an eta shrinkage of 25% (CL), 19% (V_c), and 20% (V_{max}). The epsilon shrinkage for the additive error was 10%.

In the 1 to 24 mg/kg-cohorts, peak serum concentrations (C_{max}) increased in a dose-proportional manner after the first dose, and volume of distribution was consistent with initial distribution into the plasma compartment. Increases in AUC were more than dose-proportional and clearance (CL) decreased with increasing dose, indicating target mediated disposition (TMD). Clearance also decreased with multiple doses, which may be related to tumor burden decreases. Figure 1 and Figure 2 (below) display the mean (± SD) daratumumab serum concentration versus time since end of infusion for the first and sixth weekly infusion for 8 and 16 mg/kg, including the extended terminal elimination phase following the sixth weekly infusion.

An additional population PK analysis was conducted in patients with multiple myeloma that received daratumumab in various combination therapies from five clinical trials (1035 patients of which 1025 received daratumumab at 16 mg/kg). Daratumumab concentration-time profiles were similar following the monotherapy and combination therapies in patients who received daratumumab at 16 mg/kg.

Distribution: At the end of weekly dosing for the recommended monotherapy schedule and dose of 16 mg/kg, the mean (standard deviation [SD]) serum C_{\max} value is 915 (410.3) mcg/mL, approximately 2.9-fold higher than following the first infusion. The mean (SD) predose (trough) serum concentration at the end of weekly dosing is 573 (331.5) mcg/mL.


Based on the population PK analysis of DARZALEX[®] monotherapy, daratumumab steady state is achieved approximately 5 months into the monthly dosing period (by the 21st infusion), and the mean (SD) ratio of C_{\max} at steady-state to C_{\max} after the first dose was 1.6 (0.5). The mean (SD) central volume of distribution is 56.98 (18.07) mL/kg.

Metabolism: As an IgG1 κ mAb, daratumumab is likely metabolized via degradation into small peptides and amino acids via catabolic pathways.

Elimination: The clearance rate of daratumumab decreases with increasing doses across the dose levels and with repeated dosing. The observed average CL (SD) in the 16 mg/kg cohort was 0.42 (0.424) mL/h/kg after the first dose. Based on population PK of DARZALEX[®] monotherapy, the every 2 week- and every 4 week- dosing at 16 mg/kg appeared to maintain the total clearance close to the non-specific linear clearance (0.125 mL/h/kg). Based on population PK analysis body weight was identified as a statistically significant covariate for daratumumab clearance. Simulation showed that the trough concentration of daratumumab was similar for subjects with different body weight after administration on a mg/kg basis.


Terminal half-life increases with increasing dose and with repeated dosing. The mean (SD) estimated terminal half-life of daratumumab following the first 16 mg/kg dose was 9 (4.3) days. Based on population pharmacokinetic analysis, the mean (SD) half-life associated with non-specific linear elimination was approximately 18 (9) days; this is the terminal half-life that can be expected upon complete saturation of target mediated clearance and repeat dosing of daratumumab. The mean (SD) estimated terminal half-life associated with linear clearance in combination therapy was approximately 23 (12) days.

Figure 1: Daratumumab Concentration vs Nominal Time Following the First Full Dose and Sixth Weekly Dose – Log Scale (Study GEN501 Part 1)



The error bars are mean +/- Standard Deviation

Figure 2: Daratumumab Concentration vs Nominal Time Following the First Full Dose and Sixth Weekly Dose – Linear Scale (Study GEN501 Part 1)



The error bars are mean +/- Standard Deviation

Split Dose: Interim data from phase 1b Study MMY1001 demonstrate that following the second dose of the split dose (administered Cycle 1, Day 1 and Day 2), serum daratumumab concentrations are similar to those seen following the first 16 mg/kg infusion given as a single dose.

Special Populations and Conditions

Pediatrics: Daratumumab has not been studied in pediatric patients.

Geriatrics: Based on a population PK analysis in patients receiving monotherapy, age (range: 31-84 years) was not a statistically significant covariate on the trough concentration of daratumumab. Similar to monotherapy, no clinically important influence of age on the exposure to daratumumab was observed in the population PK analyses in patients receiving combination therapies. The difference in exposure was within 6 to 15% between younger (age <65 years, n=388) and older subjects (age ≥65 to <75 years, n=484; or age ≥75 years, n=163).

Gender: Based on a population PK analysis in patients receiving monotherapy, the extrinsic factor gender [female (n=91), male (n=132)] was not a statistically significant covariate on the trough concentration of daratumumab. Similar to monotherapy, gender did not affect exposure to daratumumab in the population PK analyses in patients receiving combination therapies (female n=475; male n=560).

Ethnic origin: In a population PK analysis in patients receiving monotherapy, there was no statistically significant difference in the trough concentration of daratumumab between white (n=197) and non-white subjects (n=26). In an additional population PK analysis in multiple myeloma patients that received daratumumab with various combination therapies, the exposure to daratumumab was also similar between white (n=848) and non-white (n=187) subjects.

Hepatic Insufficiency: No formal studies of daratumumab in patients with hepatic impairment have been conducted. A population PK analysis of patients with multiple myeloma that received daratumumab in various combination therapies included 891 patients with normal hepatic function, 125 patients with mild hepatic impairment and 7 patients with moderate (TB >1.5× to 3.0× ULN), or severe (TB >3.0× ULN) hepatic impairment. No clinically important differences in the exposure to daratumumab were observed between patients with hepatic impairment and those with normal hepatic function. There are limited data available on the exposure to daratumumab in patients with moderate to severe hepatic impairment.

Renal Insufficiency: No formal studies of daratumumab in patients with renal impairment have been conducted. Population PK analyses in patients receiving combination treatments demonstrated no clinically important differences in exposure to daratumumab between patients with renal impairment (mild, n=402; moderate, n=308; severe, n=14) and those with normal renal function (n=310).

STORAGE AND STABILITY

Store vials at 2°C-8°C.

After dilution:

Since DARZALEX[®] does not contain a preservative, unless the method of preparation precludes the risk of microbial contamination, the diluted solution should be used immediately. If not used immediately, the solution may be stored in a refrigerator protected from light at 2°C–8°C for up to 24 hours prior to use, followed by 15 hours (including infusion time) at room temperature (15°C–25°C) and room light.

SPECIAL HANDLING INSTRUCTIONS

Do not freeze or shake. Protect from light. This product contains no preservative.

DOSAGE FORMS, COMPOSITION AND PACKAGING

DARZALEX[®] is supplied as a colourless to yellow preservative-free liquid concentrate for intravenous use. It is supplied in a Type 1 single-use glass vial. Each DARZALEX[®] 100 mg/5 mL or 400 mg/20 mL vial is individually packaged in a carton.

Nonmedicinal ingredients: glacial acetic acid, sodium acetate trihydrate, sodium chloride, mannitol, polysorbate 20, water for injection.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: daratumumab

Molecular mass: Approximately 148 kD

Structure: Daratumumab is an IgG1κ human monoclonal antibody against CD38 antigen

Physicochemical properties: Daratumumab is produced in a mammalian cell line (Chinese Hamster Ovary [CHO]) using recombinant DNA technology. DARZALEX[®] (daratumumab) is supplied as a colorless to yellow preservative free liquid concentrate for intravenous use. The pH is 5.5.

CLINICAL TRIALS

Patients with newly diagnosed multiple myeloma who are ineligible for ASCT

The clinical efficacy and safety of DARZALEX[®] in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for ASCT was demonstrated in Study MMY3007 (Table 14).

Table 14: Summary of clinical trials in patients with newly diagnosed multiple myeloma who are ineligible for ASCT.


| Study # Trial design | Dosage, route of administration and duration | Number of subjects |
|---|---|--|
| Study MMY3007, Phase 3, open-label, randomized, active-controlled study comparing treatment with DARZALEX® in combination with bortezomib - melphalan-prednisone (D-VMP), to treatment with VMP in patients with newly diagnosed multiple myeloma who are ineligible for ASCT. | <p>DARZALEX®* 16 mg/kg (IV): Cycle** 1 (weeks 1-6): weekly; Cycle 2-9 (weeks 7-54): every 3 weeks; Cycle ≥10 (week 55 onwards): every 4 weeks until disease progression, unacceptable toxicity or study end (D-VMP arm only).</p> <p>Bortezomib 1.3 mg/m² body surface area (BSA), subcutaneous (SC): Cycle** 1 (week 1, 2, 4, and 5): twice-weekly; Cycle 2-9 (for week 1, 2, 4, and 5 of each cycle): once weekly</p> <p>Melphalan 9 mg/m² BSA orally (PO) and prednisone 60 mg/m² BSA (PO): Days 1-4 of each bortezomib cycle.</p> <p>* DARZALEX® was administered before bortezomib on treatment days when both bortezomib and DARZALEX® were to be administered. ** Cycle = 6 weeks.</p> | <p>N=706 D-VMP arm: 350 VMP arm: 356</p> |

Key inclusion criteria included 1) patient must be newly diagnosed and not considered a candidate for high-dose chemotherapy with stem cell transplant due to a) being ≥65 years of age, or b) in patients <65 years old, the presence of comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy and stem cell transplant; and 2) patient must have an ECOG score of 0-2. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 71 (range 40-93) years old, with 29.9% of the patients ≥75 years of age. The majority were white (85%), 46% were male, and 75.4% had an ECOG performance score of 0 or 1. Patients had IgG/IgA/Light chain myeloma in 64%/22%/10% instances; 19% had ISS Stage I, 42% had ISS Stage II and 38% had ISS stage III disease. Of the 616 subjects who had baseline cytogenetic data reported, 16% had high-risk cytogenetic abnormalities, which included t(4;14) (7%), del17p (9%), and t(14;16) (2%), with similar proportions in the 2 arms (D-VMP:17%, VMP:15%).

The primary efficacy endpoint was progression free survival (PFS) based on International Myeloma Working Group (IMWG) criteria using a computer algorithm. Key secondary endpoints were objective response rate (ORR), minimal residual disease (MRD) negative rate, and overall survival (OS).

Based on the pre-defined interim analysis, study MMY3007 demonstrated an improvement in PFS in the D-VMP arm as compared to the VMP arm; the median PFS had not been reached in the D-VMP arm and was 18.1 months in the VMP arm (hazard ratio [HR]=0.5; 95% CI: 0.38, 0.65; $p<0.0001$), representing a 50% reduction in the risk of disease progression or death in patients treated with D-VMP (Figure 3).

Figure 3: Kaplan-Meier Plot for Progression-free Survival in Study MMY3007



Subgroup analyses based on PFS hazard ratio were consistent across the pre-specified subgroups and showed PFS improvement for subjects in the D-VMP group versus patients in the VMP group.

Additional efficacy results from Study MMY3007 are presented in Table 15 below.

| Table 15: Efficacy results from Study MMY3007 (ITT population) | | |
|---|-----------------------|----------------------|
| | D-VMP (n =350) | VMP (n =356) |
| PFS | | |
| Number of events (%) | 88 (25.1) | 143 (40.2) |
| Hazard Ratio [95% CI] ^a | 0.50 (0.38, 0.65) | |
| Stratified log-rank test p-value ^b | <0.0001 | |
| Median PFS in months [95% CI] | NE (NE, NE) | 18.14 (16.53, 19.91) |
| Overall response (sCR+CR+VGPR+PR) n (%) | 318 (90.9) | 263 (73.9) |
| p-value ^c | <0.0001 | |
| Stringent complete response (sCR) | 63 (18.0) | 25 (7.0) |
| Complete response (CR) | 86 (24.6) | 62 (17.4) |
| Very good partial response (VGPR) | 100 (28.6) | 90 (25.3) |
| Partial response (PR) | 69 (19.7) | 86 (24.2) |
| Time to Response, median in months (range) ^d | 0.79 (0.4, 15.5) | 0.82 (0.7, 12.6) |
| Duration of Response, median in months (range) ^d | NE (NE, NE) | 21.3 (18.4, NE) |

D-VMP = daratumumab-bortezomib-melphalan-prednisone; VMP = bortezomib-melphalan-prednisone;

MRD = minimal residual disease; CI = confidence interval; NE = not estimable.

^a Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), region (Europe vs. Other), and age (<75 years vs. ≥75 years) as randomized. A hazard ratio <1 indicates an advantage for D-VMP.

^b p-value is based on the log-rank test stratified with ISS staging (I, II, III), region (Europe vs. Other), and age (<75 years vs. ≥75 years) as randomized.

^c p-value from Cochran Mantel-Haenszel Chi-Squared test.

^d The descriptive statistics of time to response and the Kaplan-Meier estimates of duration of response were provided based on subjects with overall response of PR or better.

In the ITT population, 74 (21.1%) patients in the D-VMP group achieved CR or better and MRD negativity status at the threshold of 10^{-5} versus 22 (6.2%) in the VMP group, which met the prespecified significance level of ≤ 0.0244 . Among patients who achieved CR/sCR this corresponds to 49.7% in the D-VMP group versus 25.3% in the VMP group.

With a median follow-up of 16.5 months, 93 deaths were observed; 45 in the D-VMP arm and 48 in the VMP arm.

Patients with multiple myeloma who have received at least one prior therapy

The clinical efficacy and safety of DARZALEX[®] for the treatment of patients with multiple myeloma who have received at least one prior therapy was demonstrated in two open-label, randomized, active-controlled studies (Table 16).

Table 16: Summary of clinical trials in patients with multiple myeloma who have received at least one prior therapy who were treated with DARZALEX[®] 16 mg/kg

| Study # Trial design | Dosage, route of administration and duration | Number of subjects |
|---|---|--------------------------------------|
| Study MMY3003, Phase 3, open-label, randomized, active-controlled study comparing treatment with DARZALEX [®] in combination with lenalidomide and low-dose dexamethasone (DRd) to treatment with lenalidomide and low-dose dexamethasone (Rd) in patients with multiple myeloma who had received at least one prior therapy. | DARZALEX [®] 16 mg/kg (IV) on Days 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Days 1 and 15 of Cycles 3 to 6 (every two week dosing), and on Day 1 of Cycle 7 and subsequent cycles (every four week dosing). Lenalidomide (25 mg once daily orally on Days 1-21 of repeated 28-day [4-week] cycles) with low dose oral or intravenous dexamethasone 40 mg/week (or a reduced dose of 20 mg/week for patients >75 years or body mass index [BMI] <18.5). | N=569 DRd arm: 286 Rd arm: 283 |
| Study MMY3004, Phase 3, open-label, randomized, active-controlled study comparing treatment with DARZALEX [®] in combination with bortezomib and dexamethasone (DVd), to treatment with bortezomib and dexamethasone (Vd). | DARZALEX [®] 16 mg/kg (IV) on Days 1, 8, 15 of Cycles 1 to 3, on Day 1 of Cycles 4 to 8, and on Day 1 of Cycle 9 and subsequent cycles every four weeks. Bortezomib by subcutaneous injection or IV infusion at a dose of 1.3 mg/m ² body surface area twice weekly for two weeks (Days 1, 4, 8, and 11) of repeated 21 day (3-week) treatment cycles, for a total of 8 cycles. Dexamethasone orally at a dose of 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of the 8 bortezomib cycles (80 mg/week for two out of three weeks of each of the bortezomib cycle) or a reduced dose of 20 mg/week for patients >75 years, BMI <18.5, poorly controlled diabetes mellitus or prior intolerance to steroid therapy. | N=498 DVd arm: 251 Vd arm: 247 |

Patients with multiple myeloma who received DARZALEX[®] in combination with lenalidomide/dexamethasone (MMY3003)


See Table 16 for summary of study design and dosing. On DARZALEX[®] infusion days, 20 mg of the dexamethasone dose was given as a pre-infusion medication and the remainder given the day after the infusion. For patients on a reduced dexamethasone dose, the entire 20 mg dose was given as a DARZALEX[®] pre-infusion medication. Dose adjustments for lenalidomide and dexamethasone were applied according to manufacturer's prescribing information. Treatment was continued in both arms until disease progression or unacceptable toxicity. Patients were randomized 1:1 to receive DRd or Rd. The randomization was stratified by ISS (I, II or III) at screening, number of prior lines of therapy (1 vs 2 or 3 vs >3), and prior lenalidomide (yes vs no).

Key inclusion criteria included i) patients must have achieved a partial response or better to at least 1 prior regimen; and ii) patients must have an ECOG status 0-2. Patients refractory to lenalidomide were excluded from the study. A total of 569 patients were randomized; 286 to the DRd arm and 283 to the Rd arm. The baseline demographic and disease characteristics were generally balanced between the DARZALEX[®] and the control arm. The median patient age was 65 years (range 34 to 89 years), 11% were ≥ 75 years, 59% were male; 69% Caucasian, 18% Asian, and 3% African American. Patients had received a median of 1 prior line of therapy. Sixty-three percent (63%) of patients had received prior autologous stem cell transplantation (ASCT). The majority of patients (86%) received a prior proteasome inhibitor (PI) including bortezomib (84%), and carfilzomib (2%). Fifty-five percent, (55%) of patients had received a prior immunomodulatory agent (IMiD), including lenalidomide (18%) and thalidomide (43%). Forty-four percent (44%) of patients had received both a prior PI and IMiD. At baseline, 27% of patients were refractory to the last line of treatment. Eighteen percent (18%) of patients were refractory to a PI only, and 21% were refractory to bortezomib. Of the 439 subjects who had baseline cytogenetic data reported, 16% had high-risk cytogenetic abnormalities, which included t(4;14) (6%), del17p (10%), and t(14;16) (2%), with similar proportions in the 2 arms (DRd:15%, Rd:17%).

The primary efficacy endpoint was progression free survival (PFS) based on International Myeloma Working Group (IMWG) criteria using a computer algorithm. Key secondary endpoints were objective response rate (ORR) and overall survival (OS).

Based on the pre-defined interim analysis, study MMY3003 demonstrated an improvement in PFS in the DRd arm as compared to the Rd arm; the median PFS had not been reached in the DRd arm and was 18.4 months in the Rd arm (hazard ratio [HR]=0.37; 99.39% CI: 0.23, 0.59; $p < 0.0001$) representing 63% reduction in the risk of disease progression or death in patients treated with DRd (Figure 4).

Figure 4: Kaplan-Meier Plot for Progression-free Survival in Study MMY3003



Subgroup analyses based on PFS hazard ratio were consistent across the pre-specified subgroups and showed PFS improvement for subjects in the DRd group versus patients in the Rd group.

Additional efficacy results from Study MMY3003 are presented in Table 17 below.

Table 17: Additional efficacy results from Study MMY3003

| Intent-to-treat patient number | DRd (n=286) | Rd (n=283) |
|---|-------------------|-------------------|
| PFS ^a | | |
| Number of events (%) | 53 (18.5%) | 116 (41.0%) |
| Hazard Ratio [99.39% CI] | 0.37 (0.23, 0.59) | |
| Stratified log-rank test p-value ^b | <0.0001 | |
| Median PFS in months [95% CI] | NE (NE, NE) | 18.4 (13.9, NE) |
| Response ^a | | |
| Overall response (sCR+CR+VGPR+PR) n (%) | 261 (91.3) | 211 (74.6) |
| p-value ^c | <0.0001 | |
| Stringent complete response (sCR) | 51 (17.8) | 20 (7.1) |
| Complete response (CR) | 70 (24.5) | 33 (11.7) |
| Very good partial response (VGPR) | 92 (32.2) | 69 (24.4) |
| Partial response (PR) | 48 (16.8) | 89 (31.4) |
| Time to Response, median in months (range) ^d | 1.0 (0.9, 13.0) | 1.1 (0.9, 10.2) |
| Duration of Response, median in months (range) ^d | NR (1+, 19.8+) | 17.4 (1.4, 18.5+) |

DRd=daratumumab-lenalidomide-dexamethasone; Rd=lenalidomide-dexamethasone; CI=confidence interval;

NE=not estimable; NR=not reached.

^a The PFS and ORR interim analysis were based on an adjusted alpha level of 0.00612 and 0.02442 respectively.

^b p-value was based on the log-rank test stratified with ISS (I, II, or III), number of prior lines of therapy (1 vs. 2 or 3 vs. >3), and prior lenalidomide treatment (no vs. yes).

^c p-value from Cochran Mantel-Haenszel Chi-Squared test.

^d Time to response and duration of response were based on subjects with overall response of PR or better.

Twenty-nine percent (29.0%) of the subjects in the DRd group achieved minimal residual disease (MRD) negativity status by the threshold of 10^{-4} versus 7.8% in the Rd group.

With a median follow-up of 13.5 months, 75 deaths were observed; 30 in the DRd arm and 45 in the Rd arm.

Patients with multiple myeloma who received DARZALEX[®] in combination with bortezomib/dexamethasone (MMY3004)

See Table 16 for summary of study design and dosing. On the days of DARZALEX[®] infusion, 20 mg of the dexamethasone dose was administered as a pre-infusion medication. For patients on a reduced dexamethasone dose, the entire 20 mg dose was given as a DARZALEX[®] pre-infusion medication. Bortezomib and dexamethasone were given for 8 three-week cycles in both treatment arms; whereas DARZALEX[®] was given until treatment progression in the DVd arm. However, dexamethasone 20 mg was continued as a DARZALEX[®] pre-infusion medication in the DVd arm. Dose adjustments for bortezomib and dexamethasone were applied according to manufacturer's prescribing information. Patients were randomized 1:1 to receive DVd or Vd. The randomization was stratified by ISS (I, II or III) at screening, number of prior lines of therapy (1 vs 2 or 3 vs >3), and prior bortezomib (yes vs no).


Key inclusion criteria included i) patients must have achieved a partial response or better to at least 1 prior regimen; and ii) patients must have an ECOG status 0-2. Key exclusion criteria

included i) patients refractory to bortezomib or another proteasome inhibitor; and ii) patients intolerant to bortezomib. A total of 498 patients were randomized; 251 to the DVd arm and 247 to the Vd arm. The baseline demographic and disease characteristics were generally balanced between the DARZALEX[®] and the control arm. The median patient age was 64 years (range 30 to 88 years); 12% were ≥ 75 years, 57% were male; 87% Caucasian, 5% Asian and 4% African American. Patients had received a median of 2 prior lines of therapy and 61% of patients had received prior autologous stem cell transplantation (ASCT). Sixty-nine percent (69%) of patients had received a prior PI, including bortezomib (66%) and carfilzomib (4%); 76% of patients received an IMiD, including lenalidomide (42%), pomalidomide (3%) and thalidomide (49%). At baseline, 32% of patients were refractory to the last line of treatment and the proportions of patients refractory to any specific prior therapy were well balanced between the treatment groups. Thirty-three percent (33%) of patients were refractory to an IMiD only, with 24% of patients in the DVd arm and 33% of patients in the Vd arm refractory to lenalidomide. Of the 355 patients who had baseline cytogenetic data reported, 22% had high-risk cytogenetic abnormalities by karyotype and/or FISH analysis, which included t(4;14) (8%), del17p (14%), and t(14;16) (3%), with similar proportions in the 2 arms (DVd:23%, Vd:21%).

The primary efficacy endpoint was progression free survival (PFS) based on International Myeloma Working Group (IMWG) criteria using a computer algorithm. Key secondary endpoints were objective response rate (ORR) and overall survival (OS).

Based on the pre-defined interim analysis, study MMY3004 demonstrated an improvement in PFS in the DVd arm as compared to the Vd arm; the median PFS had not been reached in the DVd arm and was 7.2 months in the Vd arm (HR=0.39; 98.98% CI: 0.26, 0.58; p-value < 0.0001), representing a 61% reduction in the risk of disease progression or death for patients treated with DVd versus Vd (Figure 5).

Figure 5: Kaplan-Meier Plot for Progression-free Survival in Study MMY3004



Subgroup analyses based on PFS hazard ratio were consistent across the pre-specified subgroups and showed PFS improvement for subjects in the DVd group versus patients in the Vd group.

Additional efficacy results from Study MMY3004 are presented Table 18 below.

Table 18: Additional efficacy results from Study MMY3004

| Intent-to-treat patient number | DVd (n=251) | Vd (n=247) |
|---|-------------------|-------------------|
| PFS ^a | | |
| Number of events (%) | 67 (26.7%) | 122 (49.4%) |
| Hazard Ratio [98.98% CI] | 0.39 (0.26, 0.58) | |
| Stratified log-rank test p-value ^b | <0.0001 | |
| Median PFS in months [95% CI] | NE (12.3, NE) | 7.2 (6.2, 7.9) |
| Response ^a | | |
| Overall response (sCR+CR+VGPR+PR) n (%) | 199 (79.3) | 148 (59.9) |
| P-value ^c | <0.0001 | |
| Stringent complete response (sCR) | 11 (4.4) | 5 (2.0) |
| Complete response (CR) | 35 (13.9) | 16 (6.5) |
| Very good partial response (VGPR) | 96 (38.2) | 47 (19.0) |
| Partial response (PR) | 57 (22.7) | 80 (32.4) |
| Time to Response, median in months (range) ^d | 0.8 (0.7, 4.0) | 1.5 (0.7, 5.1) |
| Duration of Response, median in months (range) ^d | NR (1.4+, 14.1+) | 7.9 (1.4+, 12.0+) |

DVd=daratumumab- bortezomib-dexamethasone; Vd=bortezomib-dexamethasone; CI=confidence interval; NE=not estimable; NR=not reached

^a The PFS and ORR interim analysis were based on an adjusted alpha level of 0.0102 and 0.02442 respectively.

^b p-value was based on the log-rank test stratified with ISS (I, II, or III), number of prior lines of therapy (1 vs. 2 or 3 vs. >3), and prior bortezomib treatment (no vs. yes).

^c p-value from Cochran Mantel-Haenszel Chi-Squared test.

^d Time to response and duration of response were based on subjects with overall response of PR or better.

Thirteen point five percent (13.5%) of the subjects in the DVd group achieved MRD negativity status by the threshold of 10^{-4} versus 2.8% in the Vd group.

With a median follow-up of 7.4 months, 65 deaths were observed; 29 in the DVd arm and 36 in the Vd arm.

Patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD.

Study demographics and trial design

The clinical efficacy and safety of DARZALEX[®] for the treatment of patients with relapsed and refractory multiple myeloma was demonstrated in two open-label studies (Table 19).

Table 19: Summary of clinical trials in patients with relapsed and refractory multiple myeloma treated with DARZALEX[®] 16 mg/kg

| Study # Trial design | Dosage, route of administration and duration | Number of subjects |
|--|--|------------------------------------|
| MMY2002 Phase 2, open-label, 2-part, single arm study in patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double-refractory to a PI and an IMiD. | 16 mg/kg (IV) on Days 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Days 1 and 15 of Cycles 3 to 6 (every two week dosing), and on Day 1 of Cycle 7 and subsequent cycles (every four week dosing). | 106 subjects treated with 16 mg/kg |
| GEN501 Phase 1/2, open-label, 2-part, single arm study in patients with multiple myeloma whose disease was relapsed or refractory to at least 2 prior lines of therapies. | 16 mg/kg (IV): first dose followed by three week resting period, then weekly for eight weeks, then every two weeks for sixteen weeks, then every four weeks. | 42 subjects treated with 16 mg/kg |

Study MMY2002

Study MMY2002 was a Phase 2, open-label, 2-part, single arm study in patients with multiple myeloma who had received at least three prior lines of therapy including a PI and an IMiD, or who were refractory to both a PI and an IMiD. The selected dose from Part 1 was 16 mg/kg. Part 1 of the study was to establish an optimal dose schedule, and Part 2 was an expansion cohort. A total of 106 patients received 16 mg/kg DARZALEX[®] monotherapy weekly for 8 weeks, then every two weeks for 16 weeks, and every four weeks thereafter until disease progression or unacceptable toxicity. The primary efficacy endpoint was objective response rate (ORR) according to the International Myeloma Working Group (IMWG) criteria (2011) as assessed by an Independent Review Committee (IRC). Tumour assessment was performed every 28 days (\pm 3 days) until disease progression. Key secondary endpoints included duration of response.

The median patient age was 63.5 years (range: 31-84), 49% were male, and 79% were white. Twenty-seven percent of patients had a baseline ECOG score of 0 while 65% and 7.5% of patients had an ECOG baseline of 1 and 2, respectively. Based on the International Staging System (ISS), 24.5%, 37.7% and 37.7% of the patients had disease stage I, II and III, respectively.

Patients had received a median of 5 (range: 2-14) prior lines of therapy. Eighty percent of patients had received prior autologous stem cell transplantation (ASCT). Prior therapies included proteasome inhibitors (bortezomib [99%] and carfilzomib [50%]), and immunomodulatory drugs (lenalidomide [99%], and pomalidomide [63%]). At baseline, 97% of patients were refractory to

the last line of treatment, 95% were refractory to both a PI and an IMiD, 77% were refractory to alkylating agents, 63% were refractory to pomalidomide and 48% of patients were refractory to carfilzomib. Patient cytogenetic profiles included t(4;14) (9.5%), del17p (16.8%), del13q (31.6%) and amp1q21 (24.2%).

Efficacy results based on the Independent Review Committee (IRC) assessment are presented in Table 20.

Table 20: IRC assessed efficacy results for study MMY2002

| Efficacy Endpoint | DARZALEX [®] 16 mg/kg N=106 |
|--|---|
| Overall response rate ¹ (ORR: sCR+CR+VGPR+PR) [n (%)] 95% CI (%) | 31 (29.2) (20.8, 38.9) |
| Stringent complete response ² (sCR) [n (%)] | 3 (2.8) |
| Complete response (CR) [n (%)] | 0 |
| Very good partial response (VGPR) [n (%)] | 10 (9.4) |
| Partial response (PR) [n (%)] | 18 (17.0) |
| Median Duration of Response [months (95% CI)] | 7.4 (5.5, NE) |

¹ Primary efficacy endpoint (International Myeloma Working Group criteria)

² Defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence (International Myeloma Working Group criteria). Clearance of plasma cells from bone marrow was demonstrated in 3 subjects with a stringent CR. CI = confidence interval; NE = not estimable

The median time to response was 1 month (range: 0.9-5.6).

An improvement in survival or disease-related symptoms has not yet been established in a randomized, controlled clinical study.

Study GEN501

Study GEN501 was a Phase 1/2, open-label, 2-part, single arm study in patients with multiple myeloma whose disease was relapsed or refractory to at least 2 prior lines of therapy. Part 1 of the study was to establish the optimal dose schedule and Part 2 was an expansion cohort. In Study GEN501, 42 patients received 16 mg/kg DARZALEX[®] until disease progression. Patients received the first full infusion with a 3-week resting period, followed by weekly dosing for 7 weeks and then biweekly (every 2 weeks) infusions for 14 additional weeks. Patients then received monthly infusions for up to 72 weeks or until disease progression or unmanageable toxicity. Tumour assessment was performed on weeks 2, 4, 6 (±1 day), and 9 (±4 days), followed by assessment every 4 weeks (±4 days) until disease progression. The primary efficacy endpoint was ORR according to the IMWG criteria (2011) as assessed by an IRC. The key secondary endpoints included duration of response.

The median patient age was 64 years (range, 44 to 76 years), 64% were male and 76% were white. Patients in the study had received a median of 4 prior lines of therapy. Seventy-four percent of patients had received prior ASCT. Prior therapies included bortezomib (100%), lenalidomide (95%), pomalidomide (36%) and carfilzomib (19%). At baseline, 76% were

refractory to the last line of treatment, 64% of patients were refractory to both a PI and IMiD, 60% were refractory to alkylating agents, 36% were refractory to pomalidomide and 17% were refractory to carfilzomib.

Treatment with daratumumab at 16 mg/kg led to a 36% ORR (95% CI: 21.6, 52.0) with 1 CR and 3 VGPR. The median time to response was 1 month (range: 0.5 to 3.2 months). The median duration of response was not reached (95% CI: 5.55 months, not estimable).

TOXICOLOGY

Nonclinical toxicity was assessed in a 6-week repeat dose study in chimpanzees and a 2-week repeat dose study with a surrogate anti-CD38 antibody in cynomolgus monkeys.

Daratumumab targeted primarily hematopoietic and lymphatic systems with decreased red blood cells, hemoglobin, white blood cells, platelets and lymphoid depletion. Infusion reactions and cytokine release syndrome, with one fatal event, were reported in chimpanzees that did not receive pre-infusion medication. Mild spinal cord inflammation was observed in one monkey treated with 100 mg/kg of a surrogate antibody targeting monkey CD-38.

No carcinogenicity or genotoxicity studies have been conducted with daratumumab. No animal studies have been performed to evaluate the potential effects of daratumumab on reproduction or development, or to determine the potential effects on fertility in males or females. A summary of toxicology studies is provided in Table 21.

Table 21: Summary of Toxicology Studies

| Study Type, Test Article | Treatment Duration, Dose Schedule | Species, Number | Doses | Findings/Conclusions |
|---|--|----------------------------------|------------------------------------|---|
| General Toxicity | | | | |
| Repeat-Dose Toxicity (GLP) Daratumumab | 6 weeks, once weekly IV infusion, ~ 3 month recovery | Chimpanzee 1/sex/group | 0 (vehicle predose), 5 or 25 mg/kg | Infusion-related reactions (IRRs), including the death of one 5 mg/kg female; IRRs in the 25 mg/kg were milder due to a predose of 10 mg of daratumumab on the day prior to the first infusion. Thrombocytopenia and decreased lymphocyte cell populations (recovered as daratumumab was cleared from the circulation) |
| Repeat-Dose Toxicity (non-GLP) HuMab CD38 ^d | 2 weeks, once weekly IV infusion, 2 month recovery | Cynomolgus monkey 2/sex/group | 0, 20, or 100 mg/kg | Anemia, decreased lymphocyte cell populations in peripheral blood and lymph nodes, lymphoid atrophy or cell depletion of thymus, lymph nodes, and spleen. Mild multifocal inflammation in the spinal cord in one monkey in 100 mg/kg group |
| Other Studies | | | | |
| Tissue Cross-Reactivity (GLP) Daratumumab | | Human | 0, 0.5, 1, or 2µg/mL | Specific daratumumab-FITC staining occurred in the lymphoid cells in the spleen, tonsil, lymph nodes, and thymus. |
| Tissue Cross-Reactivity (GLP) Daratumumab | | Chimpanzee | 0, 0.25, or 1.25µg/mL | Specific daratumumab-FITC staining occurred in the lymphoid cells and macrophages, and in hematopoietic cells in the spleen, tonsil, lymph nodes, and lamina propria of the intestinal tract. |

| Study Type, Test Article | Treatment Duration, Dose Schedule | Species, Number | Doses | Findings/Conclusions |
|---|-----------------------------------|-------------------|-------------------------|--|
| Tissue Cross-Reactivity (GLP) HuMab CD38 | | Cynomolgus Monkey | 0, 0.2, 0.5, or 1 µg/mL | Specific HuMab-CD38-FITC staining was observed in the cytoplasm of blood vessels, bone marrow lymphocytes, cerebellum white matter, cerebrum white matter, cervix, colon lamina propria, fallopian tube interstitium, ileum lamina propria, lung alveolar cells, lymph node T-cells, peripheral nerve myelin, retina/choroidea glassy membrane, spinal cord white matter, spleen T-cell zone, stomach, striated muscle fibers, thymus T-cells in medulla and cortex, and tonsil T-cell zone. |

REFERENCES

Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet*; 2016;387:1551-1560.

de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic Human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. *J Immunology*; 2011;186:1840-1848.

Dimopoulos MA, Oriol A, Nahi A et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *New Engl J Med*; 2016;375:1319-1331.

Palumbo A, Chanan-Khan A, Weisel K et al. Daratumumab, bortezomib and dexamethasone for multiple myeloma. *New Engl J Med*; 2016;375:754-766.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PATIENT MEDICATION INFORMATION

PrDARZALEX[®]

daratumumab concentrate for solution for infusion

Read this carefully before you start taking **DARZALEX[®]** (Dar'-zah-lex) and each time you get an infusion. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **DARZALEX[®]**.

What is DARZALEX[®] used for?

DARZALEX[®] is used in adults 18 years or older to treat a type of cancer called multiple myeloma. This is a cancer of your plasma cells which are found in your bone marrow.

How does DARZALEX[®] work?

DARZALEX[®] contains the active substance daratumumab. Daratumumab belongs to a group of medicines called monoclonal antibodies. Daratumumab attaches to myeloma cells and works in multiple ways to kill the cancer cells. You may be prescribed daratumumab with other multiple myeloma medicines, or you may have used other multiple myeloma drugs previously. Daratumumab works differently compared to these other medicines.

What are the ingredients in DARZALEX[®]?

Medicinal ingredients: daratumumab.

Non-medicinal ingredients: glacial acetic acid, sodium acetate trihydrate, sodium chloride, mannitol, polysorbate 20, water for injection.

DARZALEX[®] comes in the following dosage forms:

DARZALEX[®] is provided as a concentrate that must be diluted in a sodium chloride solution and is then administered by intravenous infusion. It comes in vials. Each vial of 5 mL concentrate contains 100 mg of daratumumab (concentration of 20 mg/mL). Each vial of 20 mL concentrate contains 400 mg of daratumumab (concentration of 20 mg/mL).

Do not use DARZALEX[®] if:

- You are allergic to daratumumab or any of the other ingredients in **DARZALEX[®]**.

If you are not sure, talk to your doctor or nurse before you are given **DARZALEX[®]**.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you are given DARZALEX[®]. Talk about any health conditions or problems you may have, including if:

- You are pregnant, think you might be pregnant or are planning to have a baby. If you become pregnant while being treated with **DARZALEX[®]**, tell your doctor or nurse immediately. You and your doctor will decide if the benefit of receiving **DARZALEX[®]** is greater than the risk to your baby. Women who are being treated with **DARZALEX[®]** must use effective

contraception during treatment and for at least 3 months after treatment. DARZALEX[®] may harm your unborn baby.

- You are producing breast milk. You and your doctor will decide if the benefit of breast-feeding is greater than the risk to your baby. This is because the medicine may pass into the mother's milk and it is not known if it will affect the baby.
- You have breathing problems, such as asthma or Chronic Obstructive Pulmonary Disease (COPD). You will be given medicines to inhale which will help if you have breathing problems after the infusion:
 - medicines to help the airways in your lungs stay open (bronchodilators)
 - medicines to lower swelling and irritation in your lungs (corticosteroids)
- You had shingles (herpes zoster).
- You had or might now have a hepatitis B infection

If you need a blood transfusion, you will have a blood test first to match your blood type. DARZALEX[®] can affect the evaluation of the results of this blood test. Tell the person doing the test that you are taking DARZALEX[®].

Other warnings you should know about:

Infusion-related reactions:

Before and after each infusion of DARZALEX[®], you will be given medicines which help to lower the chance of infusion-related reactions. These reactions can happen during the infusion or in the 3 days after the infusion.

Tell your doctor or nurse immediately if you get any of the symptoms of an infusion-related reaction. These symptoms include:

- chills
- sore throat
- cough
- feeling sick
- itchy, runny or blocked nose
- feeling short of breath or other breathing problems including wheezing
- increased blood pressure
- dizziness or light-headedness
- headache
- rash or hives
- nausea
- vomiting
- itchiness

Although rare, you may have a severe allergic reaction. Tell your doctor or nurse immediately if you get any of the symptoms of a severe allergic reaction, which include:

- swollen face, lips, mouth, tongue or throat
- difficulty swallowing or breathing
- an itchy rash (hives)

If you have an infusion-related reaction, you may need other medicines, or the infusion may need to be slowed down or stopped. When these reactions go away or get better, the infusion can be started again.

These reactions are most likely to happen at the first infusion. Your doctor may decide not to use DARZALEX[®] if you have a severe infusion-related reaction.

Infections:

DARZALEX[®] when combined with other drugs including lenalidomide or bortezomib may increase the occurrence of infections. These infections could be severe, life-threatening or potentially fatal. Tell your healthcare provider if you develop fever, feel very tired, have a cough or have flu-like symptoms.

Hepatitis B

Tell your doctor if you have ever had or might now have a hepatitis B infection. This is because DARZALEX[®] could cause hepatitis B virus to become active again. Your doctor will check you for signs of this infection before, during and for some time after treatment with DARZALEX[®]. Tell your doctor right away if you get worsening tiredness or yellowing of your skin or white part of your eyes.

Changes in blood tests:

DARZALEX[®] can affect the results of blood tests to match your blood type. This interference can last for up to 6 months after your final dose of DARZALEX[®]. Your healthcare provider should do blood tests to match your blood type before you start treatment with DARZALEX[®]. Tell all of your healthcare providers that you are being treated with DARZALEX[®] before receiving blood transfusions.

Decreased blood cell counts:

DARZALEX[®] can decrease white blood cell counts which help fight infections, and blood cells called platelets which help to clot blood. Tell your healthcare provider if you develop fever or if you have signs of bruising or bleeding.

Pregnancy:

Lenalidomide is expected to be harmful for an unborn baby. When DARZALEX[®] is given in combination with lenalidomide, you must also read the patient medication information for lenalidomide. When lenalidomide is used, you must follow the pregnancy prevention programme for lenalidomide. Bortezomib may cause harm for an unborn baby. When DARZALEX[®] is given in combination with bortezomib, you must also read the patient medication information for bortezomib.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

How you will be treated with DARZALEX[®]:

DARZALEX[®] will be given to you by a doctor or nurse. It is given over several hours as a drip into a vein (“intravenous infusion”).

Usual dose:

Your doctor will determine your dose of DARZALEX[®]. This will depend on your body weight. The usual starting dose of DARZALEX[®] is 16 mg of daratumumab per kilogram of body weight. DARZALEX[®] may be given alone or together with other medicines used to treat multiple myeloma (i.e. bortezomib, lenalidomide, dexamethasone, melphalan, or prednisone).

When given alone or with some medicines, DARZALEX[®] is given as follows:

- once a week for the first 6, 8 or 9 weeks
- then once every 2 or 3 weeks for 15, 16 or up to 48 weeks
- then once every 4 weeks after that as long as your condition does not worsen

Depending on which other medicines DARZALEX[®] is given together with, your doctor may change the time between doses as well as how many treatments you will receive.

In the first week your doctor may give you the DARZALEX[®] dose split over two consecutive days.

Other medicines given during treatment with DARZALEX[®]:

Before each infusion of DARZALEX[®] you will be given other medicines which help to lower the chance of infusion-related reactions. These may include:

- medicines for an allergic reaction (anti-histamines)
- medicines for inflammation (corticosteroids)
- medicines for fever (such as acetaminophen)

After each infusion of DARZALEX[®] you will be given other medicines (such as corticosteroids) to lower the chance of a reaction after your infusion.

People with breathing problems:

If you have breathing problems, such as asthma or Chronic Obstructive Pulmonary Disease (COPD), you will be given medicines to inhale which help your breathing problems:

- medicines to help the airways in your lungs stay open (bronchodilators)
- medicines to lower swelling and irritation in your lungs (corticosteroids)

You may be given medicines to lower the chance of getting shingles.

Overdose:

This medicine will be given by your doctor or nurse. In the unlikely event that you are given too much (an overdose) your doctor will check you for side effects.

If you think you have been given too much DARZALEX[®] contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

It is very important to go to all your appointments. If you miss an appointment, tell your doctor and make another one as soon as possible.

What are possible side effects from using DARZALEX[®]?

These are not all the possible side effects you may feel when taking DARZALEX[®]. If you experience any side effects not listed here, contact your healthcare professional.

DARZALEX[®] is generally well-tolerated, however, like all medicines, this medicine can cause side effects.

Side effects of DARZALEX[®] (taken alone or in combination with other drugs) that may affect more than 1 in 5 people ($\geq 20\%$) include:

- feeling tired or dizzy
- nausea
- vomiting or diarrhea
- constipation
- back or joint pain
- muscle spasms
- cough
- difficulty falling asleep
- low number of red blood cells (anemia)
- low number of white blood cells (neutropenia)
- low number of a type of blood cell called platelets (thrombocytopenia)
- fever
- infections of the airways – such as nose, sinuses or throat
- peripheral sensory neuropathy (numbness or tingling in feet or hands)

Other side effects affecting more than 1 in 20 people ($\geq 5\%$) include:

- chills
- headache
- swelling
- loss of appetite
- feeling very weak
- constipation, stomach ache
- gastroesophageal reflux disease (heart burn)
- pain in the chest, arms, legs, or bones
- sore mouth
- rash
- nose bleeds
- throat irritation
- lung infection (such as pneumonia)
- flu or flu-like illness
- urinary tract infection
- low number of white blood cells (lymphopenia)
- increase or decrease in levels of calcium in your blood
- decrease in levels of sodium, potassium or magnesium in your blood

- increase in blood sugar
- increased (hypertension) or decreased (hypotension) blood pressure
- increased sweating
- anxiety or depression
- kidney impairment
- wheezing or shortness of breath (including due to build-up of fluid in the lungs)
- confusion
- weight decrease
- blurry vision

| Serious side effects and what to do about them | | | |
|--|--------------------------------------|--------------|---|
| Symptom / effect | Talk to your healthcare professional | | Stop taking drug and get immediate medical help |
| | Only if severe | In all cases | |
| Common (less than 1 in 10 but more than 1 in 100) | | | |
| Infusion-related reactions. Symptoms can include: <ul style="list-style-type: none">• chills• sore throat, cough• feeling sick• itchy, runny or blocked nose• feeling short of breath or other breathing problems• increased blood pressure | | | ✓ |
| Lung infections such as: <ul style="list-style-type: none">• pneumonia• flu• bronchitis• lower respiratory tract infections. (symptoms of lung infections may include congestion, cough, sore throat, body ache, tiredness and fever) | | ✓ | |
| Infections such as: <ul style="list-style-type: none">• sepsis or septic shock (symptoms like high fever, increased heart rate or breathing, and confusion)• urinary tract infection (symptoms like pain or burning when urinating, bloody or cloudy or foul smelling urine) | | ✓ | |
| High fever | | ✓ | |
| Irregular or rapid heartbeat (atrial fibrillation) | | ✓ | |
| Low number of blood cells such as: | | ✓ | |

| | | | |
|--|--|---|---|
| <ul style="list-style-type: none"> • platelets (thrombocytopenia) • white blood cells (neutropenia) • red blood cells (anemia) (symptoms like fatigue, loss of energy, weakness, shortness of breath) | | | |
| Bleeding problems (symptoms like blood in your stools, coughing up blood) | | ✓ | |
| Severe diarrhea (symptoms like increased number of bowel movements, watery or bloody stool, stomach pain and/or cramps) | | ✓ | |
| Rare (less than 1 in 1,000 but more than 1 in 10,000) | | | |
| Severe allergic reaction. Symptoms can include: <ul style="list-style-type: none"> • swollen face, lips, mouth, tongue or throat • difficulty swallowing or breathing • an itchy rash (hives) | | | ✓ |

Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

- Online at MedEffect® (www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program
Health Canada, Postal Locator 1908C
Ottawa, ON
K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect® (www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting).

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

DARZALEX® will be stored in a refrigerator at 2-8°C.

If you want more information about DARZALEX[®]:

- Talk to your healthcare professional
- For questions or concerns, please contact the manufacturer, Janssen Inc., at www.janssen.com/canada
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada.html>); the manufacturer's website (<http://www.janssen.com/canada>), or by calling 1-800-567-3331 or 1-800-387-8781.

This leaflet was prepared by:
Janssen Inc.
Toronto, Ontario, M3C 1L9

Last Revised:

All trademarks used under license.